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SUMMARY 
 
Breastfeeding is a major source of childhood nutrition and protection, but with South 
Africa having one of the highest HIV prevalence in the world the risk of HIV 
transmission from mother to infant through breastfeeding becomes a major issue.  
Infant mortality due to malnutrition and infections is also of great concern.  Exclusive 
breastfeeding and giving antiretroviral drugs to the HIV-infected mother and the HIV-
exposed infant is one of the most significant ways to improve infant survival rates 
and reduce transmission of HIV through breastfeeding.  Whether HIV disease 
progression and its metabolic impact on the mother will affect the nutrient 
composition of breast milk is a question that arises. 
 
The aim of this study was to determine the possible association between the stage of 
HIV disease, as measured by the immunological markers, and the nutrient 
composition of breast milk.   
 
The study population consisted of 60 HIV infected female volunteers who were 
divided into two groups.  Milk and blood samples were obtained from 30 HIV-positive 
women that was not on any ARV treatment and from 30 HIV-positive women that 
was on ARV treatment.  Their HIV status and treatment regime were obtained from 
their files.  Participants were also asked to complete a questionnaire. 
 
Macro-nutrients that were measured included lactose, proteins, fat, total solids and 
the energy content of the breast milk.  This was done on the MIRIS Human milk 
analyser.  The micro-nutrients that were measured were calcium and phosphate on 
the DXC 800 chemistry analyser.  Blood analysis was included to determine the 
stage of HIV disease progression in the HIV-positive mothers and comprised of a 
CD4/CD8+ T cell count, viral load and a full blood count.  CD4/CD8+ T cells were 
determined using flowcytometry on the BD FACScalibur.  The COBAS 
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AmpliPrep/COBAS TaqMan HIV-1 Test was used for the determination of the viral 
load and the full blood count was done using a Sysmex XT2000i haematology 
analyser.   
 
When comparing the analysed haematological variables, the white blood cells and 
red blood cells indicated a significant difference between the two groups.  Both of the 
groups were anaemic.  The CD3+ T cell count was higher and the CD4+ T cell count 
was lower than the reference range in both groups.  The median CD4+ T cells and 
HIV-1 viral load for the HIV with treatment group was higher than the HIV-infected 
without treatment group. 
 
The analyzed milk data yielded no p-value of great significance, suggesting that 
there was no statistically significant difference recorded of the measured nutrients 
between mothers receiving treatment and those who did not receive any treatment 
for HIV. 
 
The Spearman Correlation Coefficient was used to determine if HIV disease 
progression would have an influence on the nutrients that were measured.  For the 
HIV-infected without treatment group, a significant correlation was found between 
the HIV-1 viral load and percentage total solids in breast milk.  For the HIV-infected 
with treatment group the only positive correlation was between the CD4+ T cell count 
and the percentage total solids and energy content of the breast milk.  No strong 
positive correlation could be established between the immunological markers of HIV 
disease progression and the analysed nutrients in the breast milk. 
 
Taking this into consideration, HIV-positive mothers can breastfeed their babies even 
if their HIV status is at a more advance phase, but the emphasis should be placed on 
exclusive breastfeeding and getting the needed support to breastfeed.   
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CHAPTER 1 
INTRODUCTION 
 
1.1 BACKGROUND   
 
South Africa is one of the countries with the highest prevalence of HIV (Human 
immunodeficiency virus) in the world.  To prevent mother-to-child transmission of 
HIV through breastfeeding, the South African government rolled out a policy 
providing free infant formula for all HIV-positive mothers over a decade ago 
(Bloemen, 2012).  Although under-five mortality dropped by 35% worldwide between 
1990 and 2010, nearly 21 000 children under the age of five die daily, mostly from 
preventable causes with 99% of these deaths occurring in developing countries 
(WHO, 2012).  South Africa currently lags behind the Millennium Development Goal 
on reducing child mortality (Bloemen, 2012). 
 
Although South Africa lagged behind in reaching its Millennium Development Goal 
there was a major policy shift in South Africa when the Tswane Declaration was 
accepted in 2011.  This Declaration recommends that all babies should be 
exclusively breastfed for at least the first six months of their lives, and that HIV-
positive mothers should receive antiretroviral therapy throughout the breastfeeding 
period.  Their infants should also receive antiretroviral therapy (Motsoaledi, 2011). All 
of the abovementioned dramatically reduce the risk of transmission.  However, with 
South Africa’s breastfeeding rate at an extreme low of 8% it is extremely challenging 
to promote exclusive breastfeeding (Bloemen, 2012). 
 
Globally 30% of children under five are estimated to be stunted and 18% have a low 
weight-for-height.  This is mostly as a consequence of poor feeding and repeated 
infections.  Under nutrition is associated with 35% of the disease burden for children 
under five, and infant and young child feeding is a key area to improve child survival 
and to promote development and healthy growth (WHO, 2010d).  Also, the under-
five mortality rate is higher in rural areas and among poorer, less educated 
communities and three-quarters of all child deaths are mainly due to preventable 
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causes (Bloemen, 2012).  Pneumonia, responsible for nearly 1.4 million deaths 
every year, is the largest single cause of death in children under the age of five 
followed by diarrhoeal disease which accounts for 840 000 deaths in this age group 
(WHO, 2012). 
 
Early and exclusively breastfeeding, is one of the most significant ways to improve 
infant survival rates.  This is because breast milk is an important source of energy 
and nutrients for children (WHO, 2010d).  It provides all the nutrients infants need to 
grow and strengthens their immune systems (Bloemen, 2012). The risk of mortality 
due to diarrhoea and other infections can increase in infants who are either partially 
breastfed or not breastfed at all (WHO, 2010d), since they will not be getting all the 
benefits of breast milk. 
 
A woman, who is infected with HIV, can transmit the virus to her child during 
pregnancy, labour or delivery, and also through breast milk.  Therefore, the risk of 
infants acquiring HIV through breastfeeding should be considered alongside the 
higher risk of death from causes such as malnutrition and illnesses such as 
diarrhoea and pneumonia (WHO, 2010d). 
 
HIV-infected populations are burdened with malnutrition and numerous studies have 
reported that these deficiencies impair immune response and are associated with 
accelerated HIV disease progression (Dreyfuss and Fawzi, 2002). Energy 
requirements must increase by 10% to maintain body weight and physical activity in 
asymptomatic HIV-infected adults, and during symptomatic HIV energy requirements 
increase by approximately 20% to 30% to maintain body weight (WHO, 2003). 
 
The CD4+ T cell count serves as a major laboratory indicator of immune function in 
patients who have HIV infection and is one of the key factors in deciding whether to 
initiate antiretroviral therapy (HHS Panel on Antiretroviral Guidelines for Adults and 
Adolescents, 2011). 
 
Giving antiretroviral drugs to the HIV-infected mother and the HIV-exposed infant 
can significantly reduce the risk of transmission of HIV through breastfeeding (1-2%).  
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HIV-infected mothers can therefore offer their infants the same protection against the 
most common causes of child mortality and the benefits associated with 
breastfeeding (WHO, 2010d). 
 
It is not clear whether HIV disease progression and its metabolic impact on the 
mother will affect the nutrient composition of breast milk.  No information that 
correlates the quality of breast milk with HIV disease progression could be found. It 
is therefore not known whether the stage of HIV disease will have a significant 
impact on the quality of the breast milk’s nutritional value.  This kind of information is 
important for Public Health purposes, as a decision making tool to establish at which 
point additional food, over and above breast milk, should be given to the infant and 
could provide additional nutrition guidelines to support the health of the infected 
mother.  This would be to the benefit of both mother and feeding infant. 
 
1.2       AIM 
 
The main aim of this study was to investigate the possible association between the 
stage of HIV disease, as measured by the cluster of differentiation four positive 
(CD4+) T cell counts, and the nutrient composition of breast milk in breastfeeding 
female subjects. 
 
1.3 STRUCTURE OF THIS DISSERTATION 
 
The structure of this dissertation is as follows: 
 
Chapter 2 represents an extensive literature review in which the most critical 
information, that is needed to understand and interpret the aim of the study and the 
results of this study, is discussed.   
Chapter 3 provides information about the blood and milk preparation and all the test 
procedures that were used in this study.  
Chapter 4 reflects the results of this study.   
In Chapter 5 the results are discussed and  
Chapter 6 presents the limitations, conclusion and recommendations. 
4 
 
  CHAPTER 2 
LITERATURE REVIEW 
 
2.1. HISTORICAL OVERVIEW 
 
HIV has been defining our generation’s medical and public health issues since the 
world first became aware of Acquired Immune Deficiency Syndrome (AIDS).  
According to Fauci (2003) this disease has spread around the globe and continues 
to have an enormous effect throughout the world, especially in sub-Saharan Africa.  
The progress that has been made since the 1950s in health, education, life 
expectancy and standards of living has been reversed in Africa by the spread of 
HIV/AIDS (Inungu and Karl, 2006). 
 
The first description of HIV was in 1981 when young homosexual men in San 
Francisco and New York City presented with opportunistic infections that were 
typically associated with severe immune deficiency due to Pneumocystis pneumonia 
or Karposi sarcoma.  At first, various factors such as lifestyle factors, chronic drug 
abuse and other infectious agents were considered as causing this disease (Bennett 
and Greenfield, 2011; Hooper, 2000).  However, in 1983 HIV was identified as the 
etiological agent of AIDS (Bennett and Greenfield, 2011; Fauci, 2003).  
 
The zoonotic nature of HIV was established in 1986 when the close phylogenetic 
relationship between HIV-2 and the siminian immunodeficiency virus (SIV) was 
established in sooty mangabeys in Western Africa.  HIV-1 was considered to 
probably have originated from one or more cross-species transfers from the Pan 
troglodytes troglodytes specie of chimpanzees in Central Africa.  One theory posits 
that the interspecies jump from chimpanzees to humans, probably occurred by 
accident because chimpanzees are killed for food in parts of sub-Saharan Africa 
(Bennett and Greenfield, 2011; Mayer, 2005; Fauci, 2003).  Another theory holds 
that chimpanzee kidneys were used as a substrate for growing polio vaccines, 
thereby potentially providing a means for SIVs to infect humans (Martin, 2000).   
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The pathogenic mechanism of HIV disease is complex and multifactorial, meaning 
that the immune system is activated at the same time an individual might be 
experiencing immune deficiency.  While this is taking place, regular cellular activity is 
interrupted and some cells become depleted.  As a result, the depletion of CD4+ T 
cells was recognized early on as a hallmark of the disease (Fauci, 2003; Grossman, 
Meier-Schellersheim, Sousa, Victorino and Paul, 2002).     
 
The next critical advancement in the identification of HIV was the development of a 
sensitive and specific test for antibodies.  By 1985 the blood supplies in the United 
States and other developing countries were screened for HIV with the Enzyme-linked 
immunosorbent assay (ELISA) test and, according to Fauci (2003), millions of 
potential transfusion-related infections were prevented by this development. 
 
The next development was a highly sensitive technique for the precise quantification 
of small amounts of nucleic acids, an essential component in the monitoring of 
individuals with HIV.   
 
The course of the virus can be tracked by accurate measurement of the quantity of 
viral ribonucleic acid (RNA).  This is done by assays using polymerase chain 
reactions (PCR) or nucleic acid sequence-based amplification (NASBA) of the viral 
source or branched deribonucleic acid amplification (BDNA) of the signal that can 
detect a virus down to a few hundred copies per millilitre in commonly used tests and 
down to a few copies using the latest ultrasensitive tests.  Therapeutic decisions are 
guided by the PCR in conjunction with the CD4+ T cell count.  The relationship 
between the amounts of virus and the rate of disease progression, rate of viral 
turnover, the relationship between immune system activation and viral replication 
and the response to therapy are clarified by the abovementioned techniques (Sen, 
2007; Fauci, 2003).  A stable CD4+ T cell count is associated with undetectable HIV 
RNA in peripheral blood and a decline in the CD4+ T cell count is associated with 
increased HIV RNA (Sen, 2007; Osmond, 1998). 
 
Second to the identification of HIV as the cause for AIDS, most advances have 
occurred in the development of effective antiretroviral drugs.  HIV drug discovery 
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revolves around vulnerable targets in the replication cycle of the virus.  Azidovudine 
(zidovudine) (AZT), a reverse transcriptase inhibitor, was the first effective drug 
against HIV.  AZT, which was originally developed as an anticancer drug but was not 
effective in that capacity, was licensed in 1987 as the first antiretroviral drug (Fauci, 
2003; WHO International Agency for Research on Cancer, 2000).  It was identified 
through a screening process, using large numbers of compounds that had already 
been produced for other purposes. 
 
Further drug development was made on the basis of targeting the vulnerable points 
in the virus’s replication cycle.  The HIV protease enzyme is expressed, purified, and 
crystallized to facilitate the tailored design of protease inhibitors – a class of 
antiretroviral drugs (ARV) that was first approved in 1995 by the United States Food 
and Drug Administration (FDA) (Fauci, 2003). 
 
Fusion inhibitors are the newest class of drugs in development.  They block the 
fusion of the viral envelope to the cell membrane and were approved in 2003 by the 
FDA.  New and improved drugs, in all three classes, are actively pursued along with 
drugs against alternative targets such as the viral integrase.  Since these drugs have 
been used in combinations of three or more drugs, the morbidity and mortality rate of 
individuals infected with HIV has sharply declined in developed nations (Hughes, 
Barber and Nelson, 2008; Fauci, 2003). 
 
The future of a vaccine might be determined by the global distribution of clades.  The 
B clade is rarely found in developing countries which are more severely affected by 
HIV (Bennett and Greenfield, 2011; Mayer, 2005; Fauci, 2003). 
 
2.2. HIV PREVALENCE 
 
Sixty million people have been infected with the virus since the beginning of the 
epidemic and nearly 30 million people have died of AIDS since then.  An estimated 
33.3 million people were living with HIV in 2009 and there were 2.6 million new 
infections 1.8 million of which were in the World Health Organization’s (WHO) 
African Region (WHO, 2010a).  Of the global total 1.8 million of AIDS related deaths, 
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72% (1.3 million) comprised of Africans and there were 11.3 million people living with 
HIV (WHO, 2010a; UNAIDS, 2010).  It is estimated that 5.6 million people in 
Southern Africa were infected with HIV in 2009.  Globally, 34% of people living with 
HIV were residing in the 10 countries in Southern Africa and, according to Figure 2.1. 
(UNAIDS, 2010), South Africa’s epidemic was the largest in the world.  An estimated 
10.5% of the total population in South Africa was HIV-positive in 2010 (Statistics 
South Africa, 2010). 
 
Figure 2.1 Estimated HIV prevalence among the population aged 15-49 years 
as seen in 2009 (Adapted from UNAIDS, 2010) 
 
No matter where they live, girls and young women are especially vulnerable to HIV 
infection, and account for over 60% of all young people living with HIV.  In sub-
Saharan Africa, young women made up nearly 70% of all people living with HIV as 
seen in Figure 2.2 (UNICEF, 2010).  Approximately 40% of all adult women with HIV 
were living in Southern Africa (UNAIDS, 2010) and approximately one-fifth of South 
African women who were in their reproductive years were HIV-positive (Statistics 
South Africa, 2010).  
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Figure 2.2 Estimated numbers and percentage of young people 15–24 years 
old living with HIV, by region as seen in 2008 (Adapted from 
UNICEF, 2010) 
 
Table 2.1 illustrates the HIV prevalence estimates and the number of people who 
were living with HIV for the years 2001 to 2010 in South Africa.  As can be seen the 
numbers had increased since 2001, and in 2010, 19.7% of the population of women 
were HIV-positive. 
 
Table 2.1  HIV prevalence estimates and the number of people living with
 HIV in South Africa for the period 2001-2010 (Adapted from 
 Statistics South Africa, 2010) 
Population 15-49 years Percentage of 
the total 
population 
Total number of 
people living 
with HIV (in 
millions) 
Year Percentage of 
women 
Percentage of 
the population 
2001 18.7 15.4 9.4 4.10 
2002 19.2 15.8 9.6 4.38 
2003 19.4 16.1 9.8 4.53 
2004 19.6 16.3 9.9 4.64 
2005 19.7 16.5 10.0 4.74 
2006 19.7 16.6 10.1 4.85 
2007 19.7 16.7 10.2 4.93 
2008 19.7 16.9 10.3 5.02 
2009 19.6 17.0 10.3 5.11 
2010 19.7 17.3 10.5 5.24 
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In 2009, 2.5 million children had been infected with HIV, 2.3 million residing in sub-
Saharan Africa as seen in Table 2.2.  It also shows that, of the 15.9 million women 
who were infected with HIV, 12.1 million were residing in sub-Saharan Africa and 3.3 
million in South Africa.  In 2009 there were 16.6 million AIDS related orphans 
globally, 14.8 in Sub-Saharan Africa and 1.9 million in South Africa. This is shown in 
Table 2.3.  
 
Table 2.2 Table comparing the Global, sub-Saharan Africa and South 
 African estimates for HIV prevalence in adults and children; and 
 women and children in 2001 and 2009; and adults in 2009 
 (Adapted from Statistics South Africa, 2010; UNAIDS, 2010 ) 
YEAR 2001 2009 2009 2001 2009 2001 2009 
 Adults & Adults & Adults Women Women Children Children 
 Children Children 15+ years 15+ years 15+ years 0-14 years 0-14 years 
GLOBAL 28 600 000 33 300 000 30 800 000 13 600 000 15 900 000 2 000 000 2 500 000 
SUB-
SAHARAN 
AFRICA 20 300 000 22 500 000 20 300 000 10 900 000 12 100 000 1 800 000 2 300 000 
SOUTH 
AFRICA 5 300 000 5 600 000 5 300 000 2 600 000 3 300 000 170 000 330 000 
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Table 2.3 Table comparing the Global, sub-Saharan Africa and South 
African estimates for HIV prevalence in young women and men; 
adults and children who became newly infected; AIDS-related 
deaths in adults and children and; living AIDS related orphans for 
2009 and 2001 (Adapted from Statistics South Africa, 2010; UNAIDS, 
2010)  
YEAR 2009 2009 2009 2009 2009 2001 2009 2001 
 Young 
women 
15-24 
years 
Prevalence 
(%) 
Young 
men 
15-24 
years 
Prevalence 
(%) 
Adults 
& 
children 
newly 
infected 
Adults 
newly 
infected 
Aids 
related 
deaths 
in 
adults 
& 
children 
Aids 
related 
deaths 
in 
adults 
& 
children 
Orphans 
0-17 
years 
currently 
living 
Orphans 
0-17 
years 
currently 
living 
GLOBAL 0.6 0.3 2 600 000 2 200 000 1 800 000 1 800 000 16 600 000 10 000 000 
SUB-
SAHARAN 
AFRICA 3.4 1.4 1 800 000 1 500 000 1 300 000 1 400 000 14 800 000 8 900 000 
SOUTH 
AFRICA 13.6 4.5 390 000 340 000 310 000 220 000 1 900 000 580 000 
 
2.3. PATHOPHYSIOLOGY 
 
HIV-1 and HIV-2 are retroviruses in the Retroviridae family, Lentivirus genus.  They 
are enveloped, diploid, single-stranded, positive-sense RNA viruses with a 
deoxyribonucleic acid (DNA) intermediate, which is an integrated viral genome that 
persists within the host-cell DNA (Bennett and Greenfield, 2011; Barré-Sinoussi, 
1996). 
 
2.3.1. HIV-types and diagnosis 
 
There are various types and respective subtypes of HIV, according to Bennett and 
Greenfield (2011) and Klatt (2011), with HIV-1 and HIV-2 being the two major types.  
HIV-1 is responsible for the majority of infections globally while HIV-2 is rare outside 
West Africa. If the latter is reported outside West Africa there is usually some 
epidemiological link to that region (Grant and de Kock, 2001).  Figure 2.3 shows the 
11 
 
difference in how the genes of HIV-1 and HIV-2 are laid out (Stowell, 2006).  
Neutralizing antibodies, rarely found in HIV-1, are present in HIV-2 and their 
presence is equivalent to a vaccine response. As a result, people with HIV-2 live 
longer and have a response associated with delayed disease progression.  The 
different types and subtypes of HIV pose the problem that the detection methods for 
diagnosing HIV-1 and HIV-2 differ and not all methods designed to diagnose HIV-1 
will detect HIV-2.  Fortunately, perinatal transmission of HIV-2 occurs less often.  
The ARV treatment for HIV-2 also differs from that of HIV-1 because of a single 
amino acid, Leu-188 (Klatt, 2011). 
 
 
Figure 2.3 The different amino acids present in HIV-1 and HIV-2  
 (Adapted from Stowell, 2006) 
 
Table 2.4 shows the different criteria for diagnosing HIV in adults and children as 
defined by the World Health Organization (WHO) in 2007. 
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Table 2.4  WHO case definition for HIV infection (Adapted from WHO, 2007) 
HIV infection is diagnosed based on: 
Adults and children >18 months Children < 18 months 
Positive HIV antibody testing (rapid or 
laboratory-based enzyme immunoassay).  
This is confirmed by a second HIV antibody 
test (rapid or laboratory-based enzyme) 
relying on different antigens or of different 
operating characteristics; 
 
and/or; 
 
Positive virological test for HIV or its 
components (HIV-RNA or HIV-DNA or 
ultrasensitive HIV p24 antigen) confirmed by 
a second virological test obtained from a 
separate determination. 
Positive virological test for HIV or its 
components (HIV-RNA or HIV-DNA or 
ultrasensitive HIV p24 antigen) confirmed 
by a second virological test obtained from 
a separate determination taken more than 
four weeks after birth. 
 
 
 
Positive HIV antibody testing is not 
recommended for definitive or 
confirmatory diagnoses of HIV infection in 
children until 18 months of age. 
 
2.3.2. HIV life cycle; phases and staging 
 
HIV is a blood-borne disease and there are numerous ways of transmission. These 
include sexual intercourse, shared intravenous drug paraphernalia, and mother-to-
child transmission (MTCT), the latter which can occur during the birth process or 
during breastfeeding (Bennett and Greenfield, 2011). 
 
Figure 2.4 shows the various steps in the life cycle of HIV starting with binding and 
fusion (step 1 as described below) and ending with budding (as described in step 6). 
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Figure 2.4  HIV life cycle (Adapted from AIDSinfo.com, 2005) 
 
According to AIDSinfo (2005) the HIV life cycle is as follows: 
 
1.  Binding and Fusion:  The HIV virus starts its life cycle when it binds to a 
CD4 receptor and one of two co-receptors on the surface of a CD4+ T cell.  Fusion 
with the host cell takes place and the virus releases RNA into the host cell. 
 
2. Reverse Transcription:  The single stranded HIV RNA is converted to 
double-stranded HIV DNA by reverse transcriptase (RT). 
 
3. Integration:  The HIV DNA enters the host cell’s nucleus and the HIV DNA is 
hidden within the host cell’s own DNA by the enzyme integrase.  This is called a 
provirus and can remain inactive for several years. 
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4. Transcription:  Copies of HIV genomic material are created by RNA 
polymerase when the host cell receives a signal to become active.  Messenger RNA 
(mRNA) is also produced and is used to make long chains of HIV proteins. 
 
5. Assembly:  The long chain of HIV protein is cut into smaller individual 
proteins by protease and, together with copies of the HIV’s RNA genetic material, a 
new virus particle is formed. 
 
6. Budding:  The new virus particle “buds” from the host cell.  During this 
process the new virus steals part of the cell’s outer envelope which is studded with 
protein/sugar combinations called HIV glycoproteins.  These glycoproteins are 
needed for the binding of the virus to CD4 and co-receptors.  New copies of HIV can 
move on to infect other cells. 
 
The virus replication accelerates and massive viremia leads to the dissemination of 
the virus throughout the body’s lymphoid tissue.  Because there is usually only 
partial immunological control of virus replication, continual and accelerated 
production of viruses ensues.  Lymphocyte depletion occurs as a result of a rapid 
turnover of CD4+ T cells (Fauci, 2003).  
 
The anti-HIV cluster of differentiation positive (CD8+) T-cell response is inversely 
correlated to the size of the proviral reservoir which, in turn, correlates to the steady-
state viral load.  Aggressive treatment of acute infection may lower the proviral load.  
In this phase the viral load is high and the CD4+ T cells drop.  When anti-HIV 
antibodies appear and the CD8+ T cells respond, the viral load drops to a steady 
state and the CD4+ T cells return to levels within normal range although slightly lower 
than before infection.  According to Bennett and Greenfield (2011) seroconversion 
may take anywhere from a few weeks up to several months. 
 
Following seroconversion, plasma HIV-1 RNA levels are equilibrated to a value 
known as a “set point”.  The viral set point is most likely a measure of the dynamics 
between the virulence of the infecting virus strain and the host’s immune system’s 
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ability to contain the virus.   A high viral set point correlates with faster disease 
progression. Viral replication during primary and early infection in infants is more 
variable than that seen in adults.  Most infants experience a peak HIV-1 RNA viral 
load in the first few weeks after infection.  This peak will decline in some infants to a 
set point, but in others will continue to gradually decrease for several months or 
years.  High HIV-1 RNA viral load levels found in infants are highly predictive of 
disease progression, unlike in adults where the set point determines disease 
progression (Sen, 2007; Richardson et al., 2003). 
 
 
 
Figure 2.5  The typical course of HIV infection (Adapted from the Department for 
Work and Pensions, 2009) 
 
Clinical HIV infection undergoes distinct phases: – acute seroconversion/primary 
infection, asymptomatic phase, symptomatic phase and advanced phase/AIDS 
(Bennett and Greenfield, 2011; Department for Work and Pensions, 2009). Figure 
2.5 reflects these phases with the effect the infection has on the CD4+ T cells and 
plasma HIV RNA viral load levels as described below. 
 
2.3.2.1. Primary infection:  
 
Between 2 and 6 weeks after exposure to the human immunodeficiency virus acute 
seroconversion takes place.  The virus infects the exposed individual.   
16 
 
2.3.2.2. Asymptomatic phase (CD4+ T cell count greater than 350/µℓ) 
 
Persons in this stage show few or no signs of the infection for a few years to a 
decade or more.  Although viral replication is ongoing during this period the immune 
response is still effective and vigorous.  The viral load stays relatively steady but the 
CD4+ T cells steadily decline (Bennett and Greenfield, 2011; Department for Work 
and Pensions, 2009). 
 
2.3.2.3. Symptomatic phase (CD4+ T cell count 200-350 /µℓ) 
 
The person becomes increasingly susceptible to a number of infections like 
pulmonary tuberculosis, shingles, pneumococcal pneumonia, recurrent oral and 
vaginal candidiasis (thrush) and, rarely, oral hairy leukoplakia (white lesions on the 
side of the tongue caused by the Epstein-Barr virus) (Department for Work and 
Pensions, 2009).  
 
2.3.2.4. Advanced phase (CD4+ T cell count less than 200/µℓ) (AIDS) 
 
The immune system responds to opportunistic and, normally harmless, commensal 
organisms and the CD4+ T cells start to decline if the host fails to act on these 
infections (Bennett and Greenfield, 2011). 
 
The time it takes for HIV infection to take place varies greatly.  It ranges from 1 year 
or less in some persons to a still unknown upper limit in others.  That upper limit has 
reached nearly 20 years in a few individuals.  The epidemiology of HIV disease 
progression has tried to characterize the distribution of possible lengths of the 
incubation period and the AIDS survival period.  They have also tried to determine 
what cofactors accelerate or retard the disease’s progression rate.  In the absence of 
a combination of treatments, it is likely that all HIV-infected persons will lose CD4+ T 
cells and progress to AIDS.  Even with a near normal CD4+ T cell count lymphocytes 
show abnormalities that suggest their long-term immune functioning will be impaired.  
The median incubation period from HIV infection until AIDS development is 
approximately 10 years for young adults (Osmond, 1998).  Although studies have 
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documented faster rates of disease progression and deaths in infants than in adults, 
children infected in utero and intrapartum have the fastest progression (Luzuriaga et 
al., 2006). 
 
Advanced HIV infection is diagnosed on immunological CD4+ T cell counts (as seen 
in Table 2.5) and/or clinical criteria (as seen in Table 2.6) in people with confirmed 
HIV infection.  In cases where both the clinical as well as the immunological 
classification is available the immunological classification is usually used (WHO, 
2007). 
 
Table 2.5 WHO immunological classification for established HIV infection 
 (Adopted from WHO, 2007) 
AGE RELATED CD4 VALUES 
HIV-associated 
immunodeficiency 
<11 
months 
(%CD4+) 
12-35 
months 
(%CD4+) 
36-59 
months 
(%CD4+) 
>5 years  
(absolute 
number 
per mm3 
or %CD4+) 
None or not significant >35 >30 >25 >500 
Mild 30-35 25-30 20-25 350-499 
Advanced 25-29 20-24 15-19 200-349 
Severe <25 <20 <15 
<200 or 
<15% 
 
Although a four-stage clinical staging system for adults was developed in 1990 for 
clinical purposes, a three-stage system for children was only proposed in 2002 to 
support rolling out antiretroviral therapy (ART).  The 2007 WHO case definitions of 
HIV, for surveillance and revised clinical staging and immunological classification, 
replaced the 2003 version.  It stays in line with the 1990 classification of disease for 
adults and young people and proposes that the appearance of new or recurrent 
clinical staging events or immunodeficiency must be used to assess individuals once 
they receive ART.  Clinical staging can be used once HIV infection has been 
confirmed (Weinberg and Kovarik, 2010; WHO, 2007). 
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Table 2.6 Criteria for HIV staging events in adults (15 years or older) (WHO, 
 2007) 
Clinical Stage 1 (Asymptomatic) 
o Persistent generalized lymphadenopathy 
Clinical Stage 2 (Mild symptoms) 
o Unexplained moderate weight loss (<10% of bodyweight) 
o Recurrent upper respiratory tract infections (current event plus one or more in last 
six-month period). 
o Herpes zoster 
o Angular cheilitis 
o Recurrent oral ulceration (two or more episodes in last six months) 
o Papular pruritic eruption 
o Seborrhoeic dermatitis 
o Fungal nail infection 
Clinical Stage 3 (Advanced Symptoms) 
o Unexplained severe weight loss (more than 10% of body weight) 
o Unexplained chronic diarrhoea for longer than one month 
o Unexplained persistent fever (intermittent or constant and lasting for longer than one 
month) 
o Persistent oral candidiasis 
o Oral hairy leukoplakia 
o Pulmonary tuberculosis  
o Severe bacterial infection (such as pneumonia, meningitis, empyema, pyomyositis, 
bone or joint infection, bacteraemia and severe pelvic inflammatory disease) (current) 
o Acute necrotizing ulcerative gingivitis or necrotizing ulcerative periodontitis. 
o Unexplained anaemia (<8 g/dℓ), neutropaenia (<0.5 × 109 per litre) or chronic (more 
than one month) thrombocytopenia (<50 × 109 per litre) 
Clinical Stage 4 (Severe Symptoms) 
o HIV wasting syndrome 
o Pneumocystis pneumonia 
o Recurrent bacterial pneumonia; (this episode plus one or more episodes in last six 
months) 
o Chronic herpes simplex virus infection (orolabial, genital or anorectal) of more than 
one month or visceral infection of any duration 
o Oesophageal candidiasis 
o Extra pulmonary tuberculosis 
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o Kaposi sarcoma 
o Cytomegalovirus disease (other than liver, spleen or lymph node) 
o Central nervous system toxoplasmosis 
o HIV encephalopathy 
o Extra pulmonary cryptococcosis (including meningitis) 
o Disseminated nontuberculous mycobacterium infection 
o Progressive multifocal leukoencephalopathy 
o Chronic cryptosporidiosis (with diarrhoea lasting more than one month) 
o Chronic isosporiasis 
o Disseminated mycosis (coccidiomycosis or histoplasmosis) 
o Recurrent non-typhoid Salmonella bacteraemia 
o Lymphoma (cerebral or B cell non-Hodgkin) 
o Invasive cervical carcinoma 
o Atypical disseminated leishmaniasis 
o Symptomatic  HIV-associated nephropathy 
o Symptomatic HIV-associated cardiomyopathy 
 
Table 2.7 indicates the criteria for the diagnosis of advanced HIV based on the 
clinical or immunological criteria. 
 
Table 2.7 Criteria for diagnosis of advanced HIV (including AIDS) for reporting 
(Adopted from WHO, 2007) 
Clinical criteria for diagnosis of advanced HIV in adults and children with confirmed 
HIV infection: 
Presumptive or definitive diagnosis of any stage 3 or stage 4 conditiona. 
and/or; 
Immunological criteria for diagnosing advanced HIV in adults and children, five 
years or older, with confirmed HIV infection: 
CD4 count less than 350 per mm3 of blood in an HIV-infected adult or child.  
and/or; 
Immunological criteria for diagnosing advanced HIV in a child, younger than five 
years of age, with confirmed HIV infection: 
%CD4+ < 30 among those younger than 12 months; 
%CD4+ < 25 among those aged 12-35 months; 
%CD4+ < 20 among those aged 36-59 months. 
a) Criteria for HIV staging events provide criteria for presumptive or definitive
 diagnosis of all conditions. 
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AIDS in adults and children is defined as the clinical diagnosis (presumptive or 
definitive) of any stage 4 condition with confirmed HIV infection: OR immunological 
diagnosis in adults and children with confirmed HIV infection and  >5 years of age; 
first-ever documented CD4+ T cell count less than 200mm3 or % CD4+ T cells <15: 
OR among children with confirmed HIV infection aged 12– 35 months first ever 
documented %CD4+ T cells <20: OR among children of less than 12 months of age 
with confirmed HIV infection who documented  % CD4+ T cells <25 for the first time. 
 
2.4. HIV DISEASE PROGRESSION 
 
There are endogenous biologic or psychological factors that influence HIV disease 
progression.  Other infections, behaviours or environmental factors that alter the 
natural history of HIV infection may be cofactors for disease progression, but to date 
the only cofactors, for which evidence is strong, are age and genetic differences in 
the chemotactic receptors that are required by HIV in order to infect cells.  Some 
data suggests that genetic differences in human leukocyte antigen (HLA) molecules, 
smoking and nutrition may also be cofactors, but this data is less compelling 
(Osmond, 1998; Roger, 1998). 
 
2.4.1. Genetic cofactors 
 
When it was discovered that, in addition to the CD4 receptor, chemotactic receptors 
were needed for HIV to infect cells, the evidence suggested that these receptors 
affected the probability of infection and the subsequent progression rate of HIV 
disease.  The heterozygous defect in the C-C chemokine receptor type-5 (CCR-5) 
gene offers partial protection, and there seems to be interaction between the HIV 
viral stain phenotype and the protective effect of CCR-5.  Genetic differences in HLA 
also seem to be associated with the progression of HIV disease. In addition, the 
presence of HLA A1, Cw7, B8 and DR3 is also associated with CD4+ T cell decline 
(Osmond, 1998; Roger, 1998). 
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2.4.2. Age as cofactor 
 
Age is yet another cofactor in the progression of HIV disease.  The effect age has is 
that the possibility of progression to AIDS is estimated as 1.5 per every 10 years of 
age (Osmond, 1998; Portela and Simpson 1997). 
 
2.4.3. Other potential cofactors 
 
Cause-and-effect relationships are difficult to separate.  The use of drugs, smoking, 
poor nutrition, and depression may increase health problems.  Cofactors that are not 
unique to HIV disease are difficult to evaluate and some researchers see them as 
having an association and others claim that there is no association (NAM 
Publications, 2013; Osmond, 1998). 
 
2.4.4. Nutrition as cofactor 
 
Micronutrient deficiency is prevalent in many HIV-infected populations.  Studies have 
shown that these deficiencies impair immune response, weaken epithelial integrity 
and are associated with accelerated HIV disease progression (Friis, 2005; Dreyfuss 
and Fawzi, 2002). 
 
HIV infection affects nutrient absorption and metabolism negatively and could lead to 
a vitamin A deficiency.  Even when liver stores are adequate the serum, retinol, is 
suppressed during the acute phase’s response to infection.  Progression may also 
be explained by the increased risk of transmission (Friis, 2005; Dreyfuss and Fawzi, 
2002; Kotler, 2000). 
 
The potential benefits of micronutrients in showing clinical, immunological and 
virologic disease progression are important.  Table 2.8 shows the evidence between 
micronutrients and HIV disease progression (Friis, 2005; Dreyfuss and Fawzi, 2002). 
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Table 2.8 Evidence of the relationship between micronutrients and HIV 
 disease progression (Adapted from Dreyfuss and Fawzi, 2002) 
Evidence of the relation between micronutrients and HIV disease progression 
Micronutrient   Endpoint 
 
Direction of association(type of exposure) 
 
    
       
   Clinical progression to AIDS U-shaped (intake),  - (serum)     
Vitamin A   CD4+ cell count ↑(intake),↑(serum), - (supplements)     
    HIV viral load - (supplements)     
    Death U-shaped (intake), ↓(serum)     
   Clinical progression to AIDS -(Intake)     
ß-Carotene   CD4+ cell count  -(Intake), - (supplements)     
    HIV viral load  - (supplements)     
    Death ↓(Intake)     
   Clinical progression to AIDS  ↓(Intake)     
Thiamine   CD4+ cell count  ↑(Intake), - (serum)     
    Death  ↓(Intake)     
   Clinical progression to AIDS  ↓(Intake)     
Riboflavin   CD4+ cell count  ↑(Intake), - (serum)     
    Death  ↓(Intake)     
   Clinical progression to AIDS ↓(Intake)     
Niacin   CD4+ cell count ↑(Intake)     
    Death  ↓(Intake), - (serum)     
   Clinical progression to AIDS  ↓(Intake), - (serum)     
Vitamin B-6   CD4+ cell count  ↑(Intake), - (serum)     
    Death  ↓(Intake), - (serum)     
   Clinical progression to AIDS  -(Intake), ↓(serum)     
Vitamin B-12   CD4+ cell count ↑(serum)     
    Death -(Intake), ↓(serum)     
   Clinical progression to AIDS -(Intake), - (serum)     
Folate   CD4+ cell count ↑(Intake), - (serum)     
    Death  -(Intake)     
   Clinical progression to AIDS ↓(Intake)     
Vitamin C   CD4+ cell count ↑(Intake)     
    HIV viral load ↓(Supplements)     
    Death -(Intake)     
   Clinical progression to AIDS ↓(Intake)     
Vitamin E   CD4+ cell count ↑(Intake), - (serum)     
    HIV viral load ↓(Supplements)     
    Death -(Intake), - (serum)     
Iron   Clinical progression to AIDS ↓(Intake)     
    CD4+ cell count ↑(Intake)     
   Clinical progression to AIDS  ↑(Intake), ↓(serum)     
Zinc   CD4+ cell count  -(Intake), ↑(serum)     
    Death  ↑(Intake), ↓(serum)     
Selenium   CD4+ cell count  - (supplements)     
    Death  ↓(serum)     
Copper   Clinical progression to AIDS  -(Intake), ↑(serum)     
Multivitamins   Clinical progression to AIDS  ↓(Intake)     
and minerals   CD4+ cell count  ↑(Intake), ↑(Supplements)     
↑, Increase in the endpoint with increasing intake of, serum concentration of, and supplementation with the nutrient;  
↓, Decrease in the endpoint with increasing intake of, serum concentration of, and supplementation with the nutrient; 
-, no association of the endpoint with the intake of, serum concentration of, or supplementation with the nutrient;  
(intake), intake form diet and supplement use; 
(serum), serum micronutrinient concentration; 
(supplements); supplementation in randomized trials. 
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2.5. OPPORTUNISTIC INFECTIONS AND CONDITIONS 
 
Oral lesions found in HIV-positive patients can be indicative of opportunistic 
infections.  A decline in the number of CD4+ T cells and an increase in viral load 
parallels the lesions found.  These are independent indicators of the disease’s 
progression (Coogan et al., 2005). Opportunistic diseases are caused by infectious 
agents when immunosuppression is increasing.  Pneumocystis carinii, 
cytomegalovirus and varicella-zoster virus usually precede HIV infection in the host 
and are usually reactivated during HIV disease progression.  Agents of bacterial 
pneumonia may be acquired during the course of the infection.  Whether these 
opportunistic infections are markers of HIV-mediated immunosuppression, or act as 
a cofactor that accelerates HIV disease progression, has not been clearly 
determined.  During periods of acute infection HIV replication, as well as cytokines, 
increases.  HIV-mediated immunosuppression changes the host’s control over the 
infectious agents.  This inability to control the agents results in disease.  The disease 
process, in turn, activates HIV, and this hastens the rate of immunosuppression 
(Osmond, 1998). 
 
Opportunistic infections and conditions include the following: 
 Aspergillosis 
 Bacillary angiomatosis (cat scratch disease) 
 Candidiasis of bronchi, trachea, or lungs 
 Candidiasis, oesophageal 
 Cervical cancer, invasive 
 Coccidioidomycosis, disseminated or extra pulmonary 
 Cryptococcosis, extra pulmonary 
 Cryptosporidiosis, chronic intestinal (duration >1 month) 
 Cytomegalovirus disease (other than liver, spleen, or nodes) 
 Cytomegalovirus retinitis (with vision loss) 
 Encephalopathy, HIV-related 
 Herpes simplex - Chronic ulcer or ulcers (duration >1 month) or bronchitis, 
 pneumonitis, or esophagitis 
 Hepatitis B and C 
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 Histoplasmosis, disseminated or extra pulmonary 
 Human Papilloma Virus (HPV) 
 Isosporiasis, chronic intestinal (duration >1 month) 
 Kaposi sarcoma 
 Lymphoma, Burkett (or equivalent term) 
 Lymphoma, immunoblastic (or equivalent term) 
 Lymphoma, primarily of the brain 
 Mycobacterium avium complex or Mycobacterium kansasii infection, 
 disseminated or extra pulmonary 
 Mycobacterium tuberculosis infection, any site (pulmonary or extra 
 pulmonary) 
 Mycobacterium infection with other species or unidentified species, 
 disseminated or extra pulmonary 
 Microsporidiosis 
 Pneumocystis pneumonia 
 Pneumocystis carinii 
 Pneumonia, recurrent 
 Progressive multifocal leukoencephalopathy 
 Salmonella septicaemia, recurrent 
 Syphilis and Neurosyphilis 
 Shingles 
 Toxoplasmosis of the brain 
 Wasting syndrome due to HIV infection 
(Aegis, 2011; AIDS.org, 2011; Bennett and Greenfield, 2011) 
 
The two strongest cofactors – age and genetically determined receptors for HIV - are 
not alterable.  A reliable indicator for the current risk of acquiring opportunistic 
infections is the CD4+ T cell count, and a count below 200 cells\µℓ is a good indicator 
(Bennett and Greenfield, 2011).  Opportunistic infections may be averted or 
postponed with good medical care that includes prophylaxis (AIDS.org 2011; UCSF 
Medical Center, 2011; Osmond, 1998).  
 
25 
 
2.6. MOTHER TO CHILD TRANSMISSION 
 
According to UNAIDS (2010), about 2.5 million children under the age of 15 years 
were living with HIV in 2009 and an estimated 370 000 had been newly infected with 
the virus.  However, significant progress has been made in the prevention of MTCT 
of HIV, even in high burden and resource poor settings.  The elimination of MTCT of 
HIV was important to achieving the millennium’s development goals (WHO, 2010b) 
and the number has declined by 24% since 2004 (UNAIDS, 2010). 
 
Transmission of HIV from mother to child can occur during pregnancy, at the time of 
delivery, or postnatal through breastfeeding.  Although there is clear evidence that 
breast milk has protective factors, there is also evidence that breast milk can harbour 
potentially harmful bacteria and viruses (Dreyfuss and Fawzi, 2002; Georgeson and 
Filteau, 2000).  The first reported case of breastfeeding-associated HIV transmission 
was in 1985 (Humphrey, 2010). It has been shown that if no intervention is provided, 
an estimated 20-25% of infants of HIV-infected women will acquire HIV up to and 
including during delivery.  This percentage can go up to as high as 45% if these 
children are breastfed.  Transmission is increased in women with more clinically 
advanced disease, low CD4+ T cell counts and high HIV viral loads.  In such cases, 
antiretroviral and optimal infant feeding practices are needed to reduce HIV 
transmission to the infant and to promote child survival (WHO, 2010e; Becquet et al., 
2009; WHO, 2009). 
 
If preventing a child from becoming HIV-infected were the only consideration, all 
HIV-infected mothers would be advised to give their baby infant formula milk.  
Although this is the recommendation given to mothers by medical experts in 
developed countries, it is very important for mothers living in resource poor countries 
to think about the risks of not breastfeeding.  It may sound grim that an important 
health issue is based on whether you are poor or rich but, unfortunately, that is the 
stark reality.  We are living in a world that is weighed down by inequity and the gap 
between rich and poor people and nations is widening (Shearer, 2008; Latham and 
Preple, 2000). 
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2.6.1. Transmission during pregnancy 
 
The specific method for intrapartum MTCT is unknown, but transmission could most 
likely result from discrete exposure to virus in maternal blood or cervicovaginal 
secretions across infant mucosal surfaces (Luzuriaga et al., 2006). 
 
2.6.2. Transmission during delivery 
 
The aim of every obstetric unit, with regard to transmission during delivery, is to 
achieve the lowest possible transmission from mother to the foetus.  The mode of 
delivery should be discussed with the patient and a multidisciplinary team be 
involved in her care.  There should also be a counselling session, informing the 
patient of the facts and current statistics.  According to Nikhil et al (2009) it would be 
prudent to have a delivery plan in place by weeks 34-36.  
 
2.6.3. Transmission during breastfeeding 
 
Many specific and nonspecific factors in human milk, including immunoglobins, 
lactoferrin, lysozyme, secretory leukocyte protease inhibitor (SLPI), 
oligosaccharides, glycoanubiglycans, RANTES (regulating on activation normal T 
cell expressed and secreted), and Interleucin-8 (IL-8) can protect against HIV 
infection in infants (Dreyfuss and Fawzi, 2002). 
 
In many settings, breastfeeding cannot be avoided.  Risk factors for transmission of 
HIV-1 during breastfeeding include the duration of breastfeeding, characteristics of 
the mother (her age, CD4+ T cell count, viral load and breast abnormalities), the 
infant (oral candidiasis) kind of milk, e.g. human milk or type of breastfeeding (Read 
et al., 2003). 
 
According to a study done in Malawi by Read and colleagues (2003), the risk of HIV-
1 infection for infants of HIV-1 infected mothers who continued breastfeeding after 1 
month of age was 3.5% at the end of 5 months, 7.0%, at the end of 11 months, 8.9% 
at the end of 17 months and 10.3% at the end of 23 months.  Thus, the longer the 
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mothers infected with HIV-1 breastfed, the greater was the risk of HIV transmission 
to their infants.  A risk assessment done in South Africa showed that a 15% 
increased risk of HIV-1 transmission was observed with breastfeeding than formula 
feeding.  Early weaning from human milk - if feasible - would limit exposure to HIV-1 
infected human milk while still allowing the child to experience the benefits of 
breastfeeding (Becquet et al., 2009; Read et al., 2003). 
 
A lower CD4+ T cell count indicates a more advanced maternal disease stage, which 
is associated with a higher viral load in breast milk.  This increases the risk of HIV 
transmission to the infant.  The presence of breast abnormalities like mastitis, breast 
abscesses and nipple lesions is also associated with an increased risk of MTCT of 
HIV-disease since a higher human milk viral load is seen in these abnormalities.  
Oral candidiasis, in infants under six months, is associated with late postnatal 
transmission of HIV-1 through breastfeeding (Becquet et al., 2009; Carter, 2003; 
Read et al., 2003; Rousseau et al., 2003). 
 
Studies show that infants who are exclusively breastfed have a lower risk of being 
HIV-infected than those who are partially breastfed or receive mixed feeding. The 
first article on this was published in 1999 (Humphrey, 2010). Exposure to food and 
microbes in food or water may cause micro trauma to the infants’ bowel which could 
provide an entry point for HIV transmission (Buskens et al., 2007; Rousseau et al., 
2003).  
 
2.7. NUTRITION AND HIV TRANSMISSION 
 
Vertical transmission of HIV is influenced by both maternal and child factors, many of 
which relate to nutritional status.  Although systemic cell-mediated immune function 
in pregnant women is an indicator of disease progression it may also protect against 
vertical transmission.  Factors of maternal disease progression that increase the risk 
of vertical HIV transmission are of a clinical, immunologic and virological nature 
(Dreyfuss and Fawzi, 2002).  
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HIV infection affects nutrient absorption and metabolism.  HIV or opportunistic 
infections may also lead to reduced dietary intake, decreased appetite and difficulty 
swallowing.  The above, in combination with environmental factors such as the lack 
of a healthy balanced diet, creates a complex interaction between HIV and nutrition 
(WHO, 2010e). 
 
Even when liver stores are adequate, serum retinol is depressed during the acute 
phase response to infection. Thus, low serum vitamin A concentrations may be the 
result of advanced HIV disease, and this disease progression may account for the 
increased risk of vertical transmission observed (Friis, 2005; Dreyfuss and Fawzi, 
2002).  
 
Various B vitamins influence both cellular and humeral immune function.  Vitamin B6 
depletion in HIV-positive patients is associated with a reduced lymphocyte response 
to mitogens and natural killer cell cytotoxicity (Dreyfuss and Fawzi, 2002; Ehrenpreis, 
Carlson, Boorstein and Craig, 1994). 
 
Neutrophil phagocytosis is impaired by low concentrations of folic acid and vitamin 
B12.  Antioxidant vitamins are important enhancers of immune functions and vitamin 
C supplementation improves T and B lymphocyte proliferation.  Zinc is needed for 
normal neutrophil, natural killer and macrophage function.  Selenium is an important 
structural component of the antioxidant enzyme glutathione peroxidises, and is 
important in the maintenance of humoral and cell-mediated immunity (Kashou and 
Agarwal, 2011; Dreyfuss and Fawzi, 2002). 
 
2.8. FACTORS FUELLING THE SPREAD OF HIV/AIDS IN AFRICA 
 
People in Africa have their own unique culture, traditions and beliefs, some of which 
are fuelling the spread of HIV/AIDS in Africa.  When seeking ways to stop the spread 
of HIV in Africa one cannot always use the same approach as in the rest of the 
world.  The beliefs and cultures of the African people have to be taken into account. 
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2.8.1. HIV-associated stigma 
 
Until recently, many African governments were hesitant to recognize the magnitude 
of the continent’s HIV epidemic, dismissing critics as racists or being misguided.  
The silence surrounding HIV and AIDS that still perseveres has led to limited public 
discussion and continued stigmatization of those who are infected (Inungu and Karl, 
2006).  Buskens et al. (2007) argue that mothers often hide their HIV status from 
partners and relatives because of the fear of rejection, physical abuse and of losing 
financial and social support. 
 
They further maintain that where mixed feeding is the norm, relatives and neighbours 
become suspicious when mothers breastfeed exclusively or only formula feed, often 
causing them to lie rather than disclose their status.  However, the success of this 
strategy is often limited (Buskens et al., 2007). 
 
When HIV-positive mothers attempt to wean at four to six months, particularly in rural 
areas where infants are traditionally weaned after one or two years, and when the 
mothers may need permission from the father or grandparents to do so, they may 
also attempt to lie (Buskens et al., 2007; Lunney, Jenkins, Tavenga, Majo, 
Chidhanguro, Iliff, Strickland, Piwoz, Iannotti and Humphrey, 2007).  
 
2.8.2. Socio-economic status 
 
The fact that the HIV epidemic has affected the impoverished regions of the world 
the most has led to closer examination of the relationship between HIV and poverty.  
This aforementioned relationship between poverty and HIV/AIDS is bidirectional in 
that poverty is a key factor in the transmission and HIV and that HIV/AIDS can 
impoverish people in such a way as to intensify the epidemic itself.  Poor nutrition 
could result, weakening the immune system and making poverty-stricken people 
more susceptible to infectious diseases.  The high cost of treatment and possible 
lack of (or inability to) work also make infected people more likely to fall into poverty 
(Inungu and Karl, 2006; Tladi, 2006). 
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Those who are poor tend to focus more on their daily survival than their health.  
Hopelessness leads to risky behaviours, such as prostitution, so many young women 
become sexually involved with numerous male friends or clients in exchange for 
financial support.  In turn, this causes African prostitutes to have a higher prevalence 
of HIV when compared to the general population (Inungu and Karl, 2006). 
 
2.8.3. Polygamy 
 
Polygamy is a social practice in some parts of Africa, often used to ensure the 
continued status and survival of widows and orphans within an established family 
structure.  In urban settings where polygamy is no longer the norm, men tend to 
have many sexual partners and use the services of prostitutes.  There is also a false 
belief that men can rid themselves of HIV and AIDS by engaging in intercourse with 
a virgin.  This perception puts young African girls at risk of contracting HIV 
(Mpungose, 2011; Inungu and Karl, 2006). 
 
2.8.4. Widow inheritance 
 
Many countries in sub-Saharan Africa practise widow inheritance, where a man’s 
wife is viewed as property and is passed on to his adult sons or brothers after his 
death.  In this traditional ritual, the widow agrees to marry her husband’s younger 
brother to continue as part of the family.  If she refuses she is expelled and left to 
care for herself and her children by herself.  If the husband had died of AIDS, having 
infected his wife she will then in turn infect the new husband (Agot, Vander Stoep, 
Tracy, Obare, Bukusi, Ndinya-Achola, Moses and Weiss, 2010; Inungu and Karl, 
2006). 
 
2.8.5. Drug and alcohol abuse 
 
It appears that the prevalence of HIV in intravenous drug users is more common 
than previously thought.  Alcohol consumption and drug use reduce a person’s ability 
to make informed choices concerning safe sex and protection from HIV infection 
(NAM Publications, 2013; Inungu and Karl, 2006). 
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2.8.6. Feeding preferences 
 
Cultures have different feeding preferences.  In those that believe in exclusively 
breastfeeding, if the mother feeds her baby with a breast milk substitute, the very 
fact that she chooses not to breastfeed may draw attention to her HIV status.  
According to Campbell (2008), not breastfeeding often leads to violence and 
abandonment by her family and the community.  Most mothers and community 
members in Africa believe that breast milk is superior (God designed) to infant 
formula or animal milk, and that it creates a unique lifelong ‘love link’ between the 
mother and the infant (Buskens et al., 2007). 
 
Although mothers know that nurses discourage mixed feeding, few of them practice 
exclusive breastfeeding.  Buskens et al. (2007) found that the majority of HIV-
positive women would rather formula feed (if they had the means) than breastfeed 
since nurses often present HIV transmission as a certainty instead of a probability.  
Some find this information impractical and generally counter-intuitive, conflicting with 
their own understanding or beliefs.  Most mothers also give their infants water, from 
birth, believing that water is life (Buskens et al., 2007).  They perceive water as vital 
in preventing constipation, dehydration and cleansing the infant’s system (Field, 
Siziya, Katepa-Bwalya, Kankasa, Moland and Tylleskä, 2008; Buskens et al., 2007). 
 
Most mothers in South Africa and Swaziland give their infants traditional medicines, 
herbal enemas or over-the-counter medicines, presumably to treat or protect them 
from diseases.  Umfula is a solution given routinely, in rural South Africa, during the 
first month to clean the newborn infant (Buskens et al., 2007; Sikotoyi, 2004). 
Porridge is sometimes introduced as early as ten days and, on occasion, from birth.  
Mothers who do this understand that milk is essential, but they consider it to be 
insufficient to make the child grow or to satisfy hunger (Field et al., 2008;  Buskens et 
al., 2007). 
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2.8.7. Overriding authorities 
 
Since grandmothers often help raise their grandchildren, the latter are seen as 
belonging to everyone and not exclusively to the mother.  Both maternal and 
paternal grandmothers then often feel that they have a say in what the infants are 
fed, how they are cared for and what medical treatment they can receive.  As the 
majority of mothers are unemployed they rely on the income of others to provide 
them with necessities.  The member of the family who provides financially often also 
decides what the child is fed and how the child should be cared for (Buskens et al., 
2007). 
 
2.9. BREASTFEEDING VERSUS FORMULA FEEDING 
 
When comparing breastfed infants to formula fed infants the comparative risk of 
death in the first two months of life, from infectious diseases, is six to ten times 
greater than in breastfed children in developing countries.  Diarrhoea and pneumonia 
are more common and more severe in children who are artificially fed.  Even in 
situations with adequate hygiene, diarrhoeal illness is more common in artificially fed 
infants than those breastfed (WHO, 2009; Latham and Preple, 2000).  
 
According to Campbell (2008), there are difficulties in trying to prevent MTCT 
through breastfeeding, without increasing the risk of the child getting other illnesses 
since the absence of breastfeeding is associated with a significant increase in child 
mortality in uninfected infants.  Other acute infections that are less common and less 
severe in breastfed infants are otitis media, Haemophilus influenzae meningitis and 
urinary tract infection (WHO, 2009; Kuhn et al., 2010).   
 
Children who are artificially fed have an increased risk of long-term diseases with an 
immunological basis, like asthma, celiac disease, ulcerative colitis and Crohn's 
disease.  According to WHO (2009), artificial feeding is also associated with 
childhood leukaemia.  Even if infant formula is widely available it is often financially 
beyond the means of poor families (Campbell, 2008) and if infant formula is free 
there is often no mechanism to assure supply (Latham and Preple, 2000).  
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Formula milk can cause infections if it is used incorrectly.  The formula is prepared 
by mixing milk powder with local water, which is most likely to be contaminated by 
sewage in poor communities (Campbell, 2008; Shearer, 2008,).  In a study done by 
Shapiro (2007), the lack of a refrigerator and early weaning were the most predictive 
of infant illnesses.  Weaning is often seen as a period of risk among infants in the 
developing world and supportive care during this period is very important.  
Shortening the normal duration of breastfeeding for uninfected children, born to HIV-
infected mothers who live in resource-poor settings is associated with an increased 
child mortality, which extends into the second year of life.  The lack of a refrigerator 
could be indicative of unsafe storage conditions of weaning foods or of a lower 
socioeconomic status (Kuhn et al., 2010; Shapiro et al., 2007).  
 
Formula milk can cause malnutrition if over-diluted (Campbell, 2008).  Globally, the 
prevalence of underweight in children under the age of 5 years has declined from 
31% to 26% between 1990 and 2008.  Countries where insufficient or no progress 
has been made are in sub-Saharan Africa and South Asia.  In all regions of the world 
children living in rural areas are more likely to be underweight than children living in 
urban areas.  Under-nutrition is caused by a combination of factors; such as lack of 
food in terms of quantity and quality, inadequate water and sanitation and health 
services, suboptimal care and feeding practices (UNICEF, 2010). 
 
Stunting, however, is a problem of a larger magnitude than being underweight.  
Children under 2 years of age are most vulnerable of stunting and the effects are 
largely irreversible.  Children of this age are put at risk of under-nutrition by 
suboptimal breastfeeding practices and inappropriate complementary feeding 
practices.  It is, therefore, vital to focus on effective interventions for infant and young 
children feeding practices, especially those living in rural areas (UNICEF, 2010). 
 
2.9.1. Water, sanitation and hygiene 
 
Generations of women have been faced by the lack of water, sanitation and hygiene 
from as early as birthing.  It is more than likely that a pregnant woman has had to 
collect and carry water for her baby’s delivery from a hand pump outside her house, 
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herself.  Globally, more than 40% of households do not have a water supply on their 
premises, 13% do not have a hand pump in their community and they have to rely on 
an unimproved water source.  This water source is made riskier by the fact that 
many people in some communities lack even a basic toilet.  This takes on greater 
meaning when a mother weans her child (Brocklehurst and Bartram, 2010; Swarts, 
Kruger and Dolman, 2010; Chopra, 2003). 
 
Girls, around the age of six, should be going to school but much of their time will be 
spent doing chores around the house, water collection being one.  These girls could 
be exposed to infestations, such as hookworm, which reduce physical growth and 
impair intellectual development, causing them to become anaemic.  A lack of school 
toilets could contribute to sporadic attendance and sometimes in dropping out when 
a girl enters her menarche.  If she does not overcome these constraints and drops 
out of school, she will likely face early marriage and early childbearing (Brocklehurst 
and Bartram, 2010). 
 
The cycle is vicious and keeps women in poor health, out of education, and in 
poverty - doomed to bearing sickly children.  Water, sanitation and hygiene provision 
will enable women to play bigger roles in their community (Brocklehurst and Bartram, 
2010).  The World Health Organization recommends that water for people living with 
HIV, should be in containers that allows minimal manual contact.  A minimum of 20 
litres per person, per day is recommended.  To reduce diarrhoeal disease, disposal 
of faeces in a toilet, latrine or burial ground is recommended (WHO, 2010e).  
Hygiene interventions should include hygiene education and promotion of hand 
washing with soap, with soap being provided for people living with HIV, their 
caregivers and households (WHO, 2010e). 
 
2.10. HIV TREATMENT 
 
The introduction of ART has seen a great reduction in suffering and the death rate.  
Standard ART consists of the use of at least three ARV drugs in combination.  WHO 
is providing countries with ongoing guidance, tools and support in ART treatment 
recommendations (WHO, 2011a).  The up scaling of treatment has also affected 
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sub-Saharan Africa, so much so that by the end of 2009, 37% of adults and children 
who were eligible for ART were receiving it, compared to only 2% seven years earlier 
(UNAIDS, 2010).  In 2005, approximately one million adults were in need of ART in 
South Africa.  This total increased to nearly 1.5 million in 2009 (see Table 2.9). 
 
Table 2.9 Number of persons in South Africa in need of ART for the period 
  2005-2010 (Adapted from Statistics South Africa, 2010) 
Year Adults (15+ years) Children 
2005 1,069,000 93,000 
2006 1,153,000 99,000 
2007 1,238,000 129,000 
2008 1,332,000 132,000 
2009 1,438,000 139,000 
2010 1,555,000 183,000 
 
In 2005, 133 000 adults received ART in South Africa, this had increased to 920 000 
by 2009 as shown in Table 2.10. 
 
Table 2.10 Estimated number of adults receiving ART and the percentage of 
 children receiving ART and cotrimoxazole for the period 2005-
 2009 (Adapted from Statistics South Africa, 2010) 
Year 
Adults (15+ years) Children 
Estimated number receiving 
ART 
Estimated 
percentage receiving 
ART 
Estimated 
percentage receiving 
cotrimoxazole 
2005 133,000 7 2 
2006 239,000 8 4 
2007 424,000 12 12 
2008 679,000 29 21 
2009 920,000 38 29 
 
ART can be divided into various drug classes such as entry/fusion inhibitor, 
nucleoside analogue reverse transcriptase inhibitor (NRTI), non-nucleoside reverse 
transcriptase inhibitor (NNRTI), protease inhibitor (PI), chemokine co-receptor 
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antagonist (consisting of 2 subclasses: CCR-5 antagonist and CXC-chemokine 
receptor type 4 (CXCR4) antagonist), and integrase inhibitor (UCSF Medical Center, 
2011; National Institute of Allergy and Infectious Diseases, 2009). 
 
Figure 2.6 shows the various classes of ART at different points during the HIV life 
cycle as described elsewhere in this thesis. 
 
Figure 2.6 The various classes of ART work at different points during the 
 HIV life cycle (Adapted from Klatt, 2011) 
 
 Reverse Transcriptase (RT) Inhibitors (blue) interfere with the step during 
the HIV life cycle known as reverse transcription.  There are two main types of 
RT inhibitors: 
o       Nucleoside/nucleotide RT inhibitors (NRTIs) are faulty DNA building 
blocks.  This drug acts by incorporating faulty pieces into the HIV DNA and 
the chain cannot be completed, thereby blocking HIV from replicating in 
the cell. 
o       Non-nucleoside RT inhibitors (NNRTIs) bind to RT, interfering with 
the RT’s ability to convert the HIV RNA into HIV DNA. 
 Protease Inhibitors (purple) get in the way of the protease enzyme that HIV 
uses to generate infectious viral particles.  
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 Fusion/Entry Inhibitors prohibit the entry into the host cell by interfering with 
the virus’ ability to fuse with the cellular membrane. 
 Integrase Inhibitors (green) prevent occurrence of integrase, the enzyme HIV 
uses to integrate genetic material of the virus into its target host cell. 
 Chemokine co-receptor antagonists bind to either CCR-5 or CXCR4 on the 
surface of CD4+ T cells and, by so doing, obstruct a required step in viral entry.  
Whereas these drugs bind human proteins, drugs from other classes act on 
viral enzymes.  
(UCSF Medical Center, 2011; National Institute of Allergy and Infectious 
Diseases, 2009) 
 
Hundreds of ARVs are available currently.  The drugs that are recommended for the 
treatment and prevention of HIV in pregnant women, infants and young children are: 
 
 Abacavir(ABC), AZT(Retrovir), Emtricitabine(FTC) and 2’3’-dideoxy-
 3’thiacytidine(3TC) – these belong to the NRTIs 
 Efavirenz(EFV) and  Nevirapine(NVP) – belongs to the NNRTIs 
 Lopinavir/ritonavir(LPV) - is a protease inhibitor  
 Tenofovir (TDF) - belongs to the nucleotide reverse transcriptase inhibitor 
 (NtRTI) class of drugs. 
(NAM Aidsmap, 2011; WHO, 2010b; WHO, 2010e) 
 
2.10.1. Treatment and prevention of HIV in pregnant women, infants and 
young children 
 
Significant progress is being made globally in the prevention of MTCT of HIV, even 
in high burden and resource-limited settings (European Collaborative Study 
collaborators, 2010).  The incidence and impact of HIV among children younger than 
15 years in Southern Africa has been reduced.  In 2009, there was a 32% decrease 
in newly infected children and there were 26% fewer AIDS-related deaths among 
children, compared with 2004 statistics (UNAIDS, 2010).  Elimination of MTCT is 
considered a realistic public health goal and is an important part to the campaign to 
achieve the millennium development goals (MDG).  WHO recommends a broad 
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approach in the prevention of HIV in infants and young children and so the 2010 
guidelines were developed to provide international standards, primarily for low- and 
middle-income settings.  These guidelines focus on four areas: 
 
 the primary prevention of HIV transmission 
 the prevention of unintended pregnancies in women who are HIV-positive 
 the prevention of HIV transmission from women who are HIV-positive to their 
 children 
 treatment, care and support for women who are HIV-positive, their children 
 and families. 
 
According to WHO (2010b), once implemented these recommendations have the 
ability to reduce the risk of MTCT in resource-poor settings.  The revised 2010 
Preventing Mother to Child Transmission (PMTCT) recommendations as seen in 
Table 2.11 were based on two key approaches: 
 
1. Lifelong ART, which is also safe and effective in the reduction of MTCT,  for 
HIV-positive women in need of treatment for their own health. 
2. ARV prophylaxis that prevents MTCT during pregnancy, delivery and 
breastfeeding for HIV-positive women not in need of treatment for their own 
health. 
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Table 2.11 Algorithm for the 2010 PMTCT recommendations (Adapted from 
 WHO, 2010b) 
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For the first time, evidence allowed for new recommendations on ARV prophylaxis to 
either mother or infant, during breastfeeding, in areas where breastfeeding was 
judged to be the most suitable choice of infant feeding for women who were HIV-
infected.  This option was conceivable mostly because it also offered a culturally 
appropriate alternative to HIV-infected mothers (Peltier et al., 2009).   
 
PMTCT is not an intervention that stops at delivery and, ideally, postpartum and 
breastfeeding follow-ups should also be provided for the mother and the infant.  It 
should be made clear whether treatment is provided for the mother’s HIV disease or 
for MTCT prophylaxis when deciding on treatment (WHO, 2010b; WHO, 2010e).  
The reduction of HIV RNA levels and the use of ARVs both appear to have an 
independent effect on the reduction of perinatal transmission of HIV.  Maximal and 
sustained suppression of HIV RNA should be achieved during pregnancy.  The most 
critical suppression would be during late pregnancy and the time of delivery when 
MTCT occurs most frequently (Panel on Antiretroviral Guidelines for Adults and 
Adolescents, 2011). 
 
A CD4+ T cell count is essential to determine whether a woman should initiate 
lifelong ART.  Prophylaxis interventions are restricted to women who are not eligible 
for treatment according recommendations (WHO, 2010b; WHO, 2010e). The single 
dose NVP regimen is the most feasible and inexpensive strategy for low-income 
countries that are only able to deliver a minimal range of ARVs (Orne-Gliemann et 
al., 2008). 
 
The Kesho Bora study (2011) found that giving a combination of three ARVs to 
pregnant mothers who were HIV-infected from the last trimester, through delivery 
and six months during breastfeeding reduced the risk of transmitting HIV to the baby 
and improved survival.  The study compared the triple-ARV regimen against a 
control regimen of zidovudine and single-dose nevirapine.  The triple-ARV regimen 
cut HIV infections in infants by 43% compared to the control regimen and reduced 
the risk of HIV transmission during breastfeeding by more than half.  There was no 
apparent risk to the health of mothers or their babies associated with the triple-ARV 
regimen when compared with the control regimen.  Findings from the Kesho Bora 
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study strongly influenced the WHO guidelines on ARVs which were issued in July 
2010, and were aimed at preventing MTCT of HIV and infant feeding (WHO, 2011b). 
 
2.10.2. Pregnant women eligible for ART 
 
It is recommended that women with CD4+ T cells ≤350 cells/mm3 start ART for their 
own health, irrespective of WHO clinical staging, and women in WHO clinical stages 
3 or 4, do the same irrespective of the CD4+ T cell count.  Once on ART, treatment 
should be maintained throughout the pregnancy, during delivery and breastfeeding 
and thereafter for optimum health, irrespective of the gestational age (WHO, 2010b; 
WHO, 2010e). Table 2.12 indicates the recommended regimens for HIV-infected 
pregnant women who are eligible for treatment, and their infants. 
 
Table 2.12 Antiretroviral treatment options recommended for HIV-infected 
 pregnant women who are eligible for treatment (Adapted from 
 WHO, 2010b; WHO, 2010e) 
 
Maternal ART and infant ARV prophylaxis 
Mother 
Maternal antepartum daily ART, starting as soon as possible irrespective of gestational 
age, and continued during pregnancy, delivery and thereafter.  Recommended regimens 
include: 
AZT + 3TC + NVP or 
AZT + 3TC + EFV* or 
TDF + 3TC (or FTC) + NVP or 
TDF + 3TC (or FTC) + EFV* 
Infant 
Daily NVP or twice-daily AZT from birth until 4-6 weeks of age (irrespective of the mode of 
infant feeding). 
*The use of EFV should be avoided in the first trimester and NVP should be used 
instead. 
 
All HIV-infected pregnant women who are not eligible for ART for health reasons, 
should be given an effective ARV prophylaxis to prevent HIV transmission during 
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pregnancy, labour and delivery, postpartum and during the breastfeeding phase.  
ARV therapy should start in the second trimester or as soon as possible afterwards 
(WHO, 2010b; WHO, 2010e).  Table 2.13 shows the ARV-prophylaxis options 
recommended for HIV-infected pregnant women who do not need treatment for their 
own health benefit and the options recommended for their infants. 
 
Table 2.13 ARV-prophylaxis options recommended for HIV-infected pregnant 
 women who do not need treatment for their own health (Adapted 
 from WHO, 2010b; WHO, 2010e) 
Maternal AZT + infant ARV prophylaxis 
(Option A) 
Maternal triple ARV prophylaxis 
(Option B) 
 
Mother Mother 
Antepartum twice-daily AZT starting from as 
early as 14 weeks of gestation and continued 
during pregnancy.  At onset of labour, sd-
NVP and initiation of AZT + 3TC twice daily 
for 7 days postpartum.  (Note:  If maternal 
AZT was provided for more than 4 weeks 
antenatal, omission of sd-NVP and AZT + 
3TC can be considered; in this case, 
continue maternal AZT during labour and 
stop at delivery. 
Triple ARV prophylaxis starting from as 
early as 14 weeks of gestation and 
continued until delivery, or, if breastfeeding, 
continued until 1 week after all infant 
exposure to breast milk has ended.   
Recommended regimens include: 
AZT + 3TC + LPV/r or 
AZT + 3TC + ABC or 
AZT + 3TC + EFV or 
TDF + 3TC (or FTC) + EFV 
 
Infant Infant 
For breastfeeding infants 
Daily NVP from birth for a minimum of 4-6 
weeks and until 1 week after all exposure to 
breast milk has ended. 
Infants receiving replacement feeding 
only 
Daily NVP or sd-NVP + twice daily AZT from 
birth until 4-6 weeks of age. 
Irrespective of mode of infant feeding 
Daily NVP or twice daily AZT from birth until 
4-6 weeks of age 
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2.10.3. Implications for the new WHO guidelines on HIV and infant feeding 
for child survival in South Africa  
 
In April 2010 the South African Department of Health and the National AIDS Council 
released revised clinical guidelines for the prevention of MTCT of HIV.  These 
guidelines contain many promising changes, including highly active antiretroviral 
therapy (HAART) for all HIV-infected pregnant women with CD4+ T cell counts ≤350 
cells/µℓ; 6 weeks of ARV prophylaxis with nevirapine for all HIV-exposed infants; 
continued infant nevirapine until 1 week after complete cessation of breastfeeding for 
HIV-exposed infants whose mothers are not on HAART; and HAART for all 
confirmed HIV-positive infants from as early as 6 weeks of age (Doherty et al., 
2011). 
 
The new guidelines (Table 2.14) recommend that public health facilities continue 
providing free formula milk to women opting not to breastfeed.  This guideline was 
made after WHO guidelines which suggested that each country’s authorities should 
base their decision on whether health services would mainly be to support and 
counsel HIV-infected mothers on ARVs to breastfeed, or advocate all avoidance of 
breastfeeding.  Doherty et al. (2011) and Cousoudis et al. (2002) see the provision of 
free formula milk as an incentive that could cloud feeding decisions.  
 
Table 2.14 Infant feeding recommendations in the 2010 South African guideline 
on the prevention of MTCT of HIV (Adapted from Doherty et al., 2011) 
For all mothers: 
• Counselling on infant feeding must commence after the first post-test counselling 
session in pregnancy. 
• Infant feeding should be discussed with women at every antenatal visit. 
• Mixed feeding during the first 6 months of life should be strongly discouraged as 
it increases the risk of childhood infections 
• Provide nutritional support for all breastfeeding, HIV-positive mothers and for 
formula-feeding mothers with food insecurity. 
Breastfeeding HIV-positive women: 
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• All mothers who are known to be HIV-infected, either on lifelong ART or not, who 
exclusively breastfeed their infants should do so for 6 months, introduce 
appropriate complementary foods thereafter and continue breastfeeding for the 
first 12 months of life. 
• Trained health-care personnel should provide high quality, unambiguous and 
unbiased information about risks of HIV transmission through breastfeeding, 
ART prophylaxis to reduce the risk, and risks of replacement feeding. 
• Mothers who are known to be HIV-infected, and not on lifelong ART, who decide 
to stop breastfeeding at any time should do so gradually, over one month, while 
the baby continues to receive daily NVP and should continue for one week after 
all breastfeeding has stopped. 
Formula feeding HIV-positive women: 
• Free commercial infant formula will be provided to infants for at least 6 months. 
• Women should receive practical support, including demonstrations on how to 
safely prepare formula and feed the infant. 
• At 6 months of age, infants with - or at risk of - poor growth should be referred for 
continued nutritional monitoring and dietary assistance. 
• An appropriate formula milk product for the infant's age and circumstances 
should be chosen. 
• In cases in which commercial formula is provided free of charge at health 
facilities, managers, supervisors and health care personnel should ensure an 
uninterrupted supply at clinic level.   
 
Recent estimates of proportional causes of mortality of children under the age of five 
in South Africa have put diarrhoea and pneumonia third and fourth, respectively, 
behind HIV/AIDS and neonatal causes.  But, according to Doherty et al. (2011) most 
deaths of HIV-infected children are due to supervening infections, most commonly 
diarrhoea and pneumonia.  A South African Demographic and Health Survey found 
that access to piped water in a dwelling was 58% for urban residents and 11% for 
rural residents, 87% of urban residents and 56% of rural residents used electricity for 
cooking and 74% of urban residents and 5% of rural residents had a flush toilet 
(Doherty et al., 2011; Swarts, Kruger and Dolman, 2010). 
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The revised South African clinical PMTCT guidelines provide an opportunity to 
reduce postnatal HIV transmission by making ARVs available to women who needed 
them and for infants during breastfeeding (Doherty et al., 2011). 
 
2.11. NUTRIENT REQUIREMENTS FOR PEOPLE LIVING WITH HIV/AIDS 
 
People living with HIV more so pregnant and lactating women, have different nutrient 
requirements than non-infected persons.   
 
2.11.1. Adults 
 
Studies that were done on HIV-infected adults showed increased resting energy 
expenditure (REE).  This explains the weight-loss and wasting seen in these 
individuals.  It is recommended that thus infected individuals increase their energy 
needs by 10% of a healthy adult’s needs.  During periods of symptomatic disease or 
opportunistic infections the recommended increase is 20% - 30% to maintain body 
weight, taking the increase in REE into account (WHO, 2003). 
 
The World Health Organization recommends that whenever feasible, people with 
HIV who lack the means to meet their basic dietary needs, and their families should 
be assisted in achieving food security (WHO, 2010e). 
 
2.11.2. Pregnant and lactating women 
 
The recommended energy intake for adults also applies to HIV-infected pregnant 
and lactating women.  Iron-folate supplementation is a standard component of 
antenatal care for preventing anaemia and improving foetal iron stores.  WHO 
recommends daily iron-folate supplementation during the first six months of 
pregnancy to prevent anaemia, and supplements twice daily to treat severe 
anaemia.  Like other chronic infections, HIV causes disturbances of iron metabolism 
and anaemia.  Adequate micronutrient intake is best achieved through an adequate 
diet, but in resource-poor settings a multiple micronutrient supplement may be 
needed in pregnancy and lactation (WHO, 2003). 
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Optimal infant and young feeding practices rank among the most effective 
interventions to improve child health.  An estimated 9.5 million children died before 
their fifth birthday in 2006 and two thirds of those deaths occurred in the first year of 
life.  In 2008, half of the 8.8 million deaths of children under five years old occurred in 
sub-Saharan Africa where under-nutrition is associated with at least 35% of child 
deaths.  Children who survive, often also do not reach full developmental potential.  
Around 32% of children under the age of five are stunted and 10% are wasted in 
developing countries.  It is also there that mothers and families need support to 
initiate and sustain appropriate feeding practices in infants and young children 
(WHO, 2009). 
 
2.12. BREAST MILK 
 
All female mammals are uniquely equipped to provide species-specific nourishment 
and immunity through the provision of milk to their newborns (Jahn, 2009; Katz, 
2006).  The properties of human milk facilitate the transition of life from in utero to ex 
utero, and provide bioactive substances to the developing infant during critical 
periods of brain, immune and gut development (Wagner, 2010).  The process of 
producing milk and its removal by an infant is called lactation, and women produce 
breast milk as a response to the baby’s suckling.  Prolactin and oxytocin are two 
hormones which play a role in the supply and demand system.  Prolactin is essential 
for the initiation and maintenance of milk production, while oxytocin stimulates milk 
ejection (Katz, 2006). 
 
The synthesis of milk remains constant, at approximately 800mℓ per day, but the 
actual volume of milk secreted may be adjusted to the infant’s requirements by a 
feedback inhibitor of lactation.  Thus the rate of milk synthesis is related to the 
degree of breast emptiness or fullness. Stress and fatigue affect a woman’s milk 
supply (Wagner, 2010). 
 
Colostrum, the first milk that is produced after giving birth, meets all the nutritional 
requirements of the newborn during growth and maturation.  It is thicker, richer in 
minerals and has a higher protein, sodium, chlorine and fat-soluble (A, E and K) 
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vitamin concentration.  The high vitamin A concentration is often what gives 
colostrum its yellowish colour.  Colostrum is rich in white blood cells and antibodies, 
especially sIgA, which strengthens the newborn’s immune system.  It acts as a 
laxative to remove meconium (first faeces) from the digestive tract. Colostrum 
becomes transitional milk within one or two days, and then it changes into mature 
milk.  This rate varies from woman to woman (Katz, 2006; Georgeson and Filteau, 
2000). 
 
Human milk contains the right mixture of proteins, carbohydrates, fats, vitamins, 
water and minerals to meet all the nutritional needs of infants for the first six months 
of life.  It contains bioactive factors that augment the infant’s immature immune 
system providing protection against infection, and other factors such as epidermal 
growth factor that helps digestion and absorption of nutrients (WHO, 2009).  No baby 
is allergic to breast milk although he/she may have a reaction to something the 
mother had eaten.  Breast milk contains at least 100 ingredients not found in formula 
milk (Jahn, 2009).  
 
Wagner (2010) lauds Olive Wendell Holmes for having been spot on when he said 
that a pair of substantial mammary glands had the advantage over two hemispheres 
of the most learned professor’s brain in the art of compounding a nutritious fluid for 
infants. 
 
Breast milk composition is remarkably stable around the world.  It changes only 
slightly with maternal diet and under different environmental conditions (Katz, 2006). 
 
2.12.1. Fats 
 
Breast milk contains about 3.5g of fat per 100mℓ of milk, which provides about half 
the energy content of the milk.  The amount of fat increases as the feed progresses, 
thus as a result, hind milk (milk secreted towards to end of a feed) is rich in fat.  The 
fore milk (milk at the beginning of the feed) contains less fat.  Cholesterol, 
triglycerides, short-chain fatty acids and long chain fatty acids are present in human 
milk.  Long-chain polyunsaturated fatty acids called docosahexanoic acid (DHA) and 
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arachidonic acid (ARA) are fatty acids that are not available in other milk.  Since they 
are important for the neurological development of a child, they may be considered 
essential fatty acids.  The amount of ARA and DHA varies with the maternal diet. 
The antiprotozoan activity against Giardia lamblia has been shown to be directly 
related to the release of free fatty acids from milk triglycerides by bile salt dependant 
lipase and lipoprotein lipase (Wagner, 2010; WHO, 2009; Hamosh, 2001; Jenness, 
1979). 
 
2.12.2. Carbohydrates 
 
Lactose is the main carbohydrate in milk and another important source of energy.  
Breast milk contains about 7g lactose per 100mℓ.  Oligosaccharide is a carbohydrate 
which provides important protection against infection (WHO, 2009). 
 
2.12.3. Protein 
 
Breast milk contains 0.9g of protein per 100mℓ of milk.  This concentration is much 
lower than that found in animal milks.  High concentrations of protein can overload 
the infant’s immature kidneys.  The protein casein found in breast milk, has a 
different molecular structure than that found in other milks, making it more easily 
digestible.  Whereas human milk contains whey which is alpha-lactalbumin, cow’s 
milk has betalactoglobulin to which infants can become intolerant (WHO, 2009). 
 
2.12.4. Vitamins and minerals 
 
Although breast milk normally contains sufficient vitamins for an infant unless the 
mother herself is deficient, the infant needs exposure to sunlight to generate vitamin 
D.  Iron and zinc are present, albeit in low concentrations, but their bioavailability and 
absorption are high.  If maternal iron stores are adequate, term infants are born with 
a store of iron that is sufficient for their needs (WHO, 2009; Katz, 2006). 
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2.12.5. Water 
 
The mother can still exclusively breastfed even in hot climates because breast milk 
contains enough water for the baby preventing dehydration (Katz, 2006). 
 
2.12.6. Other bioactive factors 
 
 Once the milk has reached the small intestine, complete digestion of fat is 
facilitated by bile salt-stimulated lipase.  Fat in artificial milk, however, is not 
completely digested. 
 The lining of the infant’s intestine is stimulated by epidermal growth factor so 
that it is better able to digest and absorb nutrients and is less easily infected 
by foreign proteins. 
 Other growth factors target the development and maturation of the nerves and  
retina (WHO, 2009). 
 
2.12.7. Anti-infective factors 
 
 Immunoglobulin, principally secretory immunoglobulin A (sIgA), which coats 
the intestinal mucosa prevents bacteria from entering the cells.  The sIgA 
contains antibodies that are formed in the mother’s body to guard against 
bacteria in her gut and against infections she has encountered. This is of 
incredible value considering that infants’ immune system does not develop 
fully until they are two years old. 
 Immunoglobulin M, D, G, E. 
 White blood cells which can kill micro-organisms.   
 Whey proteins (lysozyme and lactoferrin) which can kill bacteria, viruses and 
fungi. Lysozyme lyses mostly gram-positive and a few gram-negative 
bacteria.  Lactoferrin activates natural killer cells and plays a role in 
complement activation, affects coagulation and inhibits E.coli and S. flexneri 
from adhering to cell walls. 
 Oligosaccharides which prevent bacteria from attaching to mucosal surfaces. 
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 Lactobacillus bifidus which are beneficial bacteria that prevent the growth of 
harmful organisms. 
 Interferon and fibronectin have antiviral activities and enhance lytic properties 
of milk leucocytes. 
(Wagner, 2010; Jahn, 2009; WHO, 2009; Georgeson and Filteau, 2000; Hamosh, 
2001) 
 
2.13. OTHER BENEFITS OF BREASTFEEDING 
 
Breastfeeding holds benefits for both the baby and the mother. 
 
2.13.1. For the baby: 
 
 Breastfed infants are at lower risk for sudden infant death syndrome. 
 The risk of Type 1 diabetes decreases for children with a family history of 
diabetes if the infant is exclusively breastfed for a minimum of four months.  
Incidences of Type 2 diabetes may also be reduced later in life. 
 Obesity, high blood pressure and high cholesterol are reduced in breastfed 
children. 
 The instances of eczema and asthma are lower for infants who are 
exclusively breastfed for four months.  
 Studies show that children who are breastfed score on average 3.2 points 
higher on cognitive functions than children who were artificially fed and this 
may affect an individual’s ability to contribute to society.  
 Breastfeeding is very convenient.  The stress of making sure that there is 
sufficient formula, that bottles are sterile, and the chore of needing to heat up 
bottles are eliminated.  
 Breast milk is always fresh and healthy. 
 Oxytocin raises the pain threshold and creates a sense of calm in both mother 
and baby. 
 Bonding between mother and baby. 
(WHO, 2009; WHO and UNICEF, 2009; Jahn, 2009; Katz, 2006) 
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2.13.2. For the mother: 
 
 Reduced risk of ovarian and premenopausal breast cancer. 
 Decreased risk of heart disease. 
 Decreased risk of osteoporosis. 
 Lower chance of developing Type 2 diabetes. 
 Breast milk suppresses ovulation and delays the return of a woman’s fertility.  
This is very important especially in HIV-infected mothers, since another 
pregnancy in a short period of time can cause severe stresses on their body.  
This may place the next infant at risk of HIV and of becoming an orphan. 
(Jahn, 2009; WHO and UNICEF, 2009; Campbell, 2008; Latham and Preple, 2000) 
 
2.14. ANIMAL MILK AND INFANT FORMULA 
 
In the 19th century, improved production of cow’s milk produced large surpluses.  
Preservation technologies developed and this led to the possibility of using cow’s 
milk as a breast milk substitute in Europe and North America.  Before this, a baby 
was breastfed by its mother or a wet nurse.  In the early 20th century, advertising in 
Britain led to greater use of artificial feeding products.  Powdered milk for infants was 
marketed in the 1950s and 1960s.  Nestlé saleswomen in nurses’ uniforms gave out 
free samples and promoted artificial feeding in maternity wards and clinics 
(Campbell, 2008). 
 
The use of milk substitutes offered greater independence to woman and many 
people believed that these substitutes were beneficial for the children, encouraging 
faster weight gain.  As a result, bottle feeding was associated with scientific 
motherhood (Campbell, 2008). As well, in the 1920s the breast was sexualized in 
such a way that it made public feeding more sensitive than it had ever been 
previously (Campbell, 2008). 
 
The quality and quantity of nutrients found in animal milks vary greatly from those 
found in human milk.  Although animal milks can be home-modified as a short term 
replacement for breast milk, in exceptionally difficult situations, they can never be 
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equivalent to or have the same anti-infective properties as breast milk.  This 
modification can be done by the addition of water, sugar and micronutrients 
(OVCSupport.net., 2013; WHO, 2009).   
 
Infant formula is usually made from industrially modified cow milk or soy products.  
The quantities are adjusted during the manufacturing process to make them 
compare better with breast milk.  The qualitative differences in the fat and protein 
cannot be altered and anti-infective and bio-active factors cannot be added (WHO, 
2009).   
 
Infections in newborns have also been traced to contaminated powdered formula.  
Between 1982 and 1994 the FDA issued 22 significant recalls of infant formula in the 
United States.  Phyto-oestrogens, found in soy formula have the same properties as 
the hormone oestrogen which could potentially reduce fertility in boys and bring 
about early puberty in girls (WHO, 2009).  The WHO’s and United Nations Children’s 
Fund’s (UNICEF) global recommendations (2009) for optimal infant feeding as set 
out in the Global Strategy are described in Appendix A. 
 
A small number of health conditions in the infant or the mother, as described in 
Appendix B, may justify recommending that she not breastfeed temporarily or 
permanently.  These conditions affect only a few infants and mothers.  Whenever 
breastfeeding is stopped the benefits of breastfeeding should be weighed against the 
risks posed by the presence of certain conditions.  Mothers who are affected by any 
of said conditions should receive treatment according to standard guidelines. 
 
2.15. CURRENT FEEDING PRINCIPLES AND RECOMMENDATIONS  
 
The Guideline Development Group identifies nine key principles that are summarized 
in Table 2.15 that should be read together with the seven evidence-based 
recommendations. 
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2.15.1. Principles 
 
These values cannot be subjected to formal research but represent public health 
approaches and preferences (WHO, 2010). 
 
Table 2.15 Summary of the nine key principles for feeding of infants by 
mothers who are HIV-infected 
Key Principle 1 
Balancing HIV prevention with protection from other causes of child mortality 
Infant feeding practices of mothers who are HIV-infected should support the greatest 
likelihood of HIV-free survival of their children that do no harm the health of the mother. To 
achieve this, prevention of HIV transmission needs to be balanced with meeting the infant’s 
nutritional requirements and protection against non-HIV morbidity and mortality.  
Key Principle 2 
Integrating HIV interventions into maternal and child health services 
National authorities should aim to integrate HIV testing, care and treatment interventions for 
all women into maternal and child health services.  This should include access to CD4+ T cell 
count testing as well as antiretroviral therapy or prophylaxis for the women, in order to 
prevent MTCT of HIV. 
Key Principle 3 
Setting national or sub-national recommendations for infant feeding in the context of 
HIV 
National or sub-national health authorities should decide whether health services will mainly 
counsel and support mothers known to be HIV-infected to either: 
o breastfeed and receive antiretroviral drugs, or 
o avoid all breastfeeding in order to give the infant the greatest chance of HIV-free 
survival. 
International recommendations and the following should be taken into account: 
o the socio-economic and cultural context of the population that is served by the 
maternal and child health services;  
o the quality and availability of health services; 
o local epidemiology, including HIV prevalence among pregnant women; and 
o the main causes of maternal and child under-nutrition and child mortality.  
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Key Principle 4 
When antiretroviral drugs are not (immediately) available, breastfeeding may still 
provide infants born to HIV-infected mothers with a greater chance of HIV-free 
survival 
ARVs should be available to prevent HIV transmission to infants and for maternal health.  
While ARV interventions are being scaled up, national authorities should not be deterred 
from recommending that HIV-infected mothers breastfeed as the most suitable infant feeding 
practice in their setting.  Unless environmental and social circumstances are safe for, and 
supportive of replacement feeding, mothers should be counselled to exclusively breastfeed 
in the first six months of life and continue breastfeeding thereafter even when ARVs are not 
available. Even in circumstances where ARVs are unlikely to be available the 
recommendation for HIV-exposed infants should also be breastfeeding.  
Key Principle 5 
Informing mothers known to be HIV-infected about infant feeding alternatives 
Women known to be HIV-infected should be informed about the infant feeding practices that 
are recommended by the national or sub-national authority to improve HIV-free survival of 
HIV-exposed infants and the health of HIV-infected mothers.  They should be informed that 
there are alternatives.  
Key Principle 6 
Providing services to specifically support mothers to appropriately feed their infants 
All pregnant women and mothers should have access to skilled counselling and support in 
appropriate infant feeding practice and ARV interventions to promote HIV-free survival of 
infants. 
Key Principle 7 
Avoiding harm to infant feeding practices in the general population 
Counselling and support given to mothers known to be HIV-infected must be done in such a 
way as to not undermine optimal breastfeeding practices in the general population. 
Key Principle 8 
Advising mothers who are HIV uninfected or whose HIV status is unknown: 
Mothers who are known to be HIV uninfected or whose HIV status is unknown should 
be counselled to exclusively breastfeed their infants for the first six months.  Then 
complementary foods should be introduced while continuing breastfeeding for 24 months or 
beyond.  
Mothers whose status is unknown should be offered HIV testing.  
Mothers who are HIV uninfected should be counselled about ways to prevent HIV 
infection, and they should know that services such as family planning are available to help 
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them remain uninfected.  
Key Principle 9 
Investing in improvements in infant feeding practices in the context of HIV 
Resources and commitment should be increased by governments, other stakeholders and 
donors, for the implementation of the global strategy for infant and young child feeding, the 
United Nations HIV and infant feeding framework for priority action and the global scale-up 
of the prevention of mother-to-child transmission of HIV in order to effectively prevent 
postnatal HIV infections, improve HIV-free survival and achieve relevant United Nations 
General Assembly Special Session goals.  
 
 
2.15.2. Recommendations 
 
Recommendations are summarised in Table 2.16.  These are directed towards 
policymakers, academics and health workers and are intended to inform and assist 
national technical groups, international and regional partners who provide HIV care 
and treatment services and/or maternal and child health services in countries 
affected by HIV, in formulating national or sub-national infant feeding 
recommendations in the context of HIV. 
 
Table 2.16 Recommendations for feeding of infants by mothers who are HIV-
 infected 
Recommendation 1 
Ensuring mothers receive the care they need 
Mothers known to be HIV-infected should be provided with lifelong Antiretroviral Therapy 
(ART) or Antiretroviral (ARV) prophylaxis interventions to reduce HIV transmission through 
breastfeeding, according to WHO recommendations. 
Recommendation 2 
Which breastfeeding practices and for how long? 
In settings where national or sub-national authorities have decided that maternal, newborn 
and child health services will principally promote and support breastfeeding and ARV 
interventions, infants of mothers known to be HIV-infected (and whose infants are HIV 
uninfected or of unknown HIV status) should be exclusively breastfed for the first 6 months 
of life.  Complementary foods should thereafter be introduced, and breastfeeding should be 
continued for the first 12 months of life. 
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Recommendation 3 
When mothers decide to stop breastfeeding 
In settings where national or sub-national authorities have decided that maternal, newborn 
and child health services will principally promote and support breastfeeding and ARV 
interventions, mothers known to be HIV-infected who decide to stop breastfeeding should 
stop gradually within one month.  ARV prophylaxis should continue for one week after 
breastfeeding has fully stopped.  Abrupt stopping of breastfeeding is not advisable. 
Recommendation 4 
What to feed infants when mothers stop breastfeeding 
Infants of HIV-infected mothers who decide to stop breastfeeding should be provided with 
safe and adequate replacement feeds to enable normal growth and development.  
Alternatives to breastfeeding include: 
For infants under six months of age: 
 Commercial infant formula milk as long as home conditions outlined in 
Recommendation #5 are fulfilled; 
 Expressed, heat-treated breast milk (see Recommendation #6).  
 Home-modified animal milk is not recommended as a replacement food in the first six 
months of life. 
For children over six months of age: 
 Commercial infant formula milk as long as home conditions outlined in 
 Recommendation #5 are fulfilled; 
 Animal milk (boiled for infants under 12 months), as part of a diet that provides 
adequate micronutrient intake;  
 Meals, including milk-only feeds, other foods and combination of milk feeds and other 
foods, should be provided four or five times per day. All children need 
complementary foods from six months of age.  
Recommendation 5 
Conditions needed to safely formula feed 
Only when specific conditions are met can mothers, known to be HIV-infected, give 
commercial infant formula milk as a replacement feed to their HIV-uninfected infants or 
infants who are of unknown HIV status: 
 safe water and sanitation are guaranteed at the house and in the community; and 
 infant formula milk can constantly be provided to support normal growth and 
development of the infant; and  
 it can be prepared cleanly and regularly enough so that it is safe and carries a low 
risk of diarrhoea and malnutrition; and  
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 infant formula milk can exclusively be given for the first six months; and 
 the family is supportive of this practice; and 
 healthcare that offers comprehensive child services is readily available.  
Recommendation 6 
Heat-treated, expressed breast milk 
An interim feeding strategy can be the expression and heat-treating of breast milk: 
 in special circumstances such as a low birth weight or if the infant is ill in the neonatal 
period and unable to breastfeed; or 
 when the mother is unwell or has a breast health problem such as mastitis; or 
 to assist mothers to stop breastfeeding; or 
 ARV is temporarily not available.  
Recommendation 7 
When the infant is HIV-infected 
Infants that are known to be HIV-infected should be exclusively breastfed for the first six 
months of life and continue to be breastfed as per the recommendations for the general 
population - that is up to two years or beyond. 
 
2.16. MATERNAL NUTRITION AND BREAST MILK 
 
The question of composition and volume of breast milk produced by mothers, on 
different planes of nutrition at different phases of lactation, is a major issue especially 
in resource poor countries, where food supply is limited.  There are concerns about 
the adequacy of such milk for infants (Ettyang, van Marken, Lichtenbelt, Esamai, 
Saris and Westerterp, 2005; Jelliffe and Jelliffe, 1978). 
 
During lactation, a mother’s energy intake should increase by about 10% to cover 
the energy cost of breastfeeding, and if she is moderately or very active, up to 20%.  
In very ill-fed mothers, lactation can sometimes lead to weight loss that can be as 
much as 7kg over a year, leading to nutritional oedema in very poorly nourished 
women.  The quantity of breast milk decreases and ultimately ceases in seriously 
malnourished women.  Thus, malnourishment and the cessation of breast milk can 
have fatal consequences for the nursing baby (Jelliffe and Jelliffe, 1978).  Women 
who are well nourished and follow a varied diet will usually retain enough milk (if 
enough was stored during her pregnancy) to cover for any extra needs.  Even if a 
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woman is moderately malnourished the quality of breast milk is good (WHO, 2009).  
A study done by Jelliffe and Jelliffe(1978) showed that protein supplementation, to 
the lactating mother’s diet, increased the volume of milk produced and the weight of 
the infant but not the protein content of the milk. 
 
Studies done on fat content, in poorly fed women in developing countries, have 
demonstrated considerable variation, but recent work suggests that the fat content 
may be reduced to as low as 1g/100mℓ.  The calories of this milk are associated with 
significant lessening of energy intake.  The polyenoic fatty acids may be diminished 
in malnourished mothers’ breast milk and this could have possible bad 
consequences in relation to brain growth (Emmett and Rogers, 1997; Jelliffe and 
Jelliffe, 1978). 
 
Lactose is constant in concentration and shows no diurnal variation.  Even in poorly 
nourished mothers lactose does not seem to vary much (Lönnerdal, 1986; Jelliffe 
and Jelliffe, 1978). 
 
Various vitamins in breast milk are affected differently by malnourishment: 
 Vitamin A is influenced by the adequacy of the diet of the mother during 
pregnancy and lactation.  Intake is generally higher in spring and summer 
months due to greater availability of green leafy and yellow vegetables. 
 Fat-soluble Vitamin D levels are low in human milk, but the recent discovery 
that breast milk contains a water-soluble conjugate of vitamin D explains the 
clinically well-recognized rarity of rickets in breastfed infants. Milk levels of 
vitamin D may be of minor physiological importance since it appears that 
sunlight may be the main contributor of antirachitic sterols in infants.  
 Thiamine concentrations have been found to be low in regions with a high 
incidence of infantile beriberi.  This is due to insufficient maternal stores and 
intake. 
 Sufficient amounts of riboflavin are found in human milk, provided that the 
maternal diet is adequate.  
 Niacin can be synthesized from tryptophan, thus human milk has a high 
potential niacin concentration. 
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 Low levels of vitamin B12 have been found in milk of poorer, vegetarian 
women.  Vitamin B6 is also affected by maternal intake. 
 Vitamin C levels vary with the season.  When fresh fruits and vegetables are 
readily available, poorly nourished women often show lower concentrations of 
ascorbic acid than well-nourished women.   
 Calcium levels in poorly fed mothers range from normal to somewhat low 
concentrations. 
(Lönnerdal, 1986; Jelliffe and Jelliffe, 1978) 
 
The maternal diet seems to have no effect on the concentration of magnesium, 
sodium, potassium, chlorine, iron, zinc, copper, and the trace elements (Lönnerdal, 
1986). 
 
Human milk is all that is required to sustain growth and good nutrition in the infant for 
the first six months providing that the mother is well-nourished.  These mothers will 
have produced foetuses with optimal stores, and will have built adequate nutritional 
reserves themselves, including subcutaneous fat.  The volume and composition of 
milk in poorly nourished women is surprisingly good.  Metabolic adaptations have 
been made because of their maternal depletion, but the quantity and quality is often 
suboptimal (Ettyang et al., 2005; Jelliffe and Jelliffe, 1978). 
 
Having taken all of the above into consideration, it appears that breast milk is best 
for infants.  That being the case, the question whether HIV disease progression will 
affect the nutrient composition of breast milk in HIV mothers, risking not only MTCT 
but also malnutrition, arises.  As shown, mothers who breastfeed need an increase 
in their energy intake to provide sufficient nutrients for themselves and their infants, 
to sustain basic metabolic functions.  That is so even before taking the increased 
energy needs of HIV-positive mothers into consideration.   
 
 
 
 
 
60 
 
CHAPTER 3 
METHODOLOGY 
 
3.1. STUDY DESIGN AND WORKPLAN 
 
This study used a descriptive design. The breast milk of HIV-infected volunteers, 
who were lodging and day visiting mothers at the Paediatric and Neonatal wards of 
National; Pelonomi and Universitas Hospitals in Bloemfontein, the Mangaung 
University of the Free State Community Partnership Programme (MUCPP), Heidedal 
and Botshabelo clinics, was measured for its nutrient composition.  Blood and breast 
milk samples as well as clinical data from the patient files were obtained from each 
participant, after permission was granted by the appropriate authorities.  Laboratory 
measurements were taken and procedures performed in the laboratories of 
Bloemfontein and Cape Town PathCare, and at the Mowbray Maternity Hospital Milk 
Depot in Cape Town. 
 
A summary layout of the data collection which included a consent form, demographic 
profile as well as blood and milk analysis is given in Figure 3.1 below. 
 
 
 
 
 
 
. 
Figure 3.1 Summary layout of the data collection 
NUTRITIONAL COMPOSITION OF 
BREAST MILK 
HIV–POSITIVE women not on HAART 
 
30 HIV-positive women on HAART and 
Dual treatment 
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treatment 
 
 Consent form 
 Demographic profile 
 CD4 & Full blood count 
 Viral load 
 Milk analysis 
 
 Consent form  
 Demographic profile 
 CD4 & Full blood count 
 Viral load 
 Milk analysis 
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3.2. STUDY POPULATION 
 
The study population consisted of HIV-infected female volunteers who were lodging 
or day visiting mothers at the Paediatric and Neonatal wards of National, Pelonomi 
and Universitas Hospitals in Bloemfontein, the Mangaung University of the Free 
State Community Partnership Programme (MUCPP), Heidedal and Botshabelo 
clinics.  Their HIV status and treatment regime were obtained from their files. Various 
CD4+ T cell counts were included to accommodate the different stages of HIV. The 
population was divided into two groups:  
Group 1: 30 HIV-positive patients who were not on ARV treatment were selected. 
Group 2: 30 HIV-positive patients on ARV treatment were selected. 
 
3.3. SAMPLE SIZE 
 
Sixty patients, who gave written informed consent and met the inclusion criteria, 
were selected for this study. 
 
3.4. INCLUSION AND EXCLUSION CRITERIA 
 
The inclusion and exclusion criteria for the subjects were as follows: 
 
3.4.1 Inclusion Criteria 
 
 All lactating women who exclusively breastfed. 
 Subjects had to have been post-partum at least 5 days to avoid the analysis 
of colostrum.  The analysis had to be performed on mature milk.  Colostrum is 
the deep yellow-colored milk secreted the first days after childbirth.  Secretion 
thereof lasts about 5 days after birth and changes to mature milk gradually. 
 Subjects should not have been breastfeeding for longer than 45 days.  
      (Summary:  Mothers who had been breastfeeding between 5-45 days). 
 Subjects had to be between 18 – 40 years of age. 
 Mothers who were not still breastfeeding a previous child. 
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3.4.2. Exclusion Criteria 
 
 Evidence of psychiatric disorder, antagonistic personality, poor motivation to 
 participate in this study or limited ability to comply with protocol requirements. 
 History of, or current compulsive alcohol abuse (>10 drinks weekly), or regular 
 exposure to other substance abuse. 
 Participation in another study with an experimental drug within eight weeks of 
the first administration of study medication. 
 Heavy smoking (i.e. more than 20 cigarettes per day). 
 Diabetic HIV-positive individuals. 
 
3.5. WITHDRAWAL CRITERIA 
 
Subjects were informed of their right to withdraw from the study at any time, 
irrespective of the reason.  None of the subjects withdrew from the study. 
 
3.6. SUBJECT IDENTIFICATION 
 
Each subject received a unique ten digit laboratory number and retained this number 
throughout the study.  Initials and date of birth were obtained from the subjects’ 
identification books. 
 
3.7. SUBJECT INFORMED CONSENT 
 
A written information sheet as well a verbal explanation concerning the purpose, 
nature and possible risk involved in taking part in this study was given to the 
subjects.  They were also informed about the purpose, procedures, restrictions, 
obligations, remuneration and insurance coverage that were relevant to the study.  
The informed consent discussion and written patient’s information were both 
included to provide adequate information and ascertain that the subjects understood 
all the ramifications.  By signing and dating the informed consent form, the 
respondents voluntarily accepted the terms of the study and agreed to participate in 
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the study. The researcher who conducted the informed consent discussion also 
signed with the respective subjects.   
 
The subject information sheets and informed consent forms were made available in 
English, Afrikaans and Sesotho.  An interpreter was also present to afford the 
respondents the opportunity to use their preferred language.  The subjects were 
provided with the subject information sheet and informed consent form in the 
language of their choice and they retained copies of both.  
 
3.8. DATA AND SAMPLE COLLECTION 
 
3.8.1. Questionnaire 
 
After the consent was completed the patients were interviewed and asked to 
complete a questionnaire to gather socio-economic and breastfeeding information 
about the participants (see Appendix C). 
 
3.8.2. Breast milk samples 
 
Mothers were asked to abstain from breastfeeding their babies for three hours before 
milk collection.  The breast milk samples were collected just before the mothers 
began breastfeeding.  The procedure was explained to each participating mother 
and they were asked to collect 5-10mℓ of their breast milk in sterile 50mℓ plastic 
containers, themselves. 
 
3.8.3. Blood samples 
 
A registered phlebotomist collected two 5mℓ ethylenediaminetetraacetic acid (EDTA) 
tubes of blood from each participant.  
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3.9. DATA FROM PATIENT FILES 
 
The medical history of the patient was obtained from her patient files. If the patient 
had given consent to participate in the study, her CD4+ T cell count as well as the 
treatment was obtained from her patient file – where available. 
 
3.10. LABORATORY ANALYSIS 
 
3.10.1 SAMPLE PREPARATION 
 
3.10.1.1 Breast milk 
 
Breast milk samples were divided into two sterile containers then frozen immediately 
after collection to ensure a homogenous sample for analysis at the two different 
laboratories (PathCare Bloemfontein and Mowbray Maternity Hospital Milk Depot, 
Cape Town).  Samples were transported to Cape Town, within two weeks of 
sampling, on dry ice with an overnight courier to ensure that they stayed frozen until 
analysis.  
 
Milk can be frozen in a freezer compartment for up to two weeks before analysis, but 
once thawed milk cannot be frozen again. It can, however, be refrigerated for up to 9 
hours, before analysis, once thawed.  
 
3.10.1.2 Blood 
 
The two EDTA tubes of blood that were collected were processed according to the 
standard operating procedures (SOP) of PathCare.  The full blood count and CD4+ T 
cell count were done upon arrival at the laboratory.  The viral load was sent to the 
PathCare laboratory in Cape Town for analysis.  Plasma was separated from the red 
blood cells by centrifugation of the EDTA sample at 800g for 20 minutes and then 
the plasma was toppled into a polypropylene tube that was labelled, before analysis, 
with the appropriate barcode and subject number.  
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3.10.2 SAMPLE ANALYSIS 
 
3.10.2.1 Breast milk analysis 
 
The analysis of the biochemical variables were measured according to standard 
operating procedures of each laboratory.  The following variables were included in 
the analysis of the breast milk: 
 
Macro-nutrients:  
 Lactose (%); 
 Proteins (%); 
 Fat (%); 
 Total Solids (%) and  
 Energy (kcal/100mℓ). 
 
Micro-nutrients:  
 Calcium (mmol/ℓ); 
 Phosphate (mmol/ℓ). 
 
The micro-nutrients were analyzed by PathCare in Bloemfontein and the macro-
nutrients were analyzed at the Mowbray Maternity Hospital Milk Depot in Cape 
Town. 
 
3.10.2.1.a Measurement of macro-nutrients 
 
Instrument:  MIRIS Human milk analyser 
Manufactured by:  MIRIS 
Principle and methodology:  The MIRIS Human Milk Analyzer is based on a 
unique patented technique in combination with approved IR-technology (Infrared 
transmission spectroscopy).  Fat, protein, lactose, energy and total solids are 
analyzed directly in one single run without any chemicals.  Results are obtained 
within one minute (MIRIS, 2010). 
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Quality assurance: On-board quality assurance 
 
3.10.2.1.b Measurement of micro-nutrients: 
 
Instrument:  DXC 800 
Manufactured by:  Beckman Coulter 
Principle and methodology: 
Phosphate:   PHOSm reagent is used to measure the phosphorus concentration 
using a timed-rate method.  In the reaction, inorganic phosphorus 
reacts with ammonium molybdate in an acidic solution to form a 
coloured phosphomolybdate complex (BECKMAN COULTER, 2006).   
 
Calcium:  Total calcium concentration is measured through indirect potentiometry 
utilizing a calcium ion selective electrode in conjunction with a sodium 
 reference electrode.  A calcium ion selective electrode measures un-
 bound free calcium ions in solution (BECKMAN COULTER, 2005).  
 
The DXC 800 is a fully automated analyzer, and after the samples were put into the 
sample racks, they and the reagent probes samples’ exact volumes were placed into 
cuvettes and the respective reactions occurred.  Reactions are measured against a 
calibration curve and the calcium and phosphate concentrations are taken. 
 
Quality assurance: Synchron 1, 2 and 3. 
 
3.10.2.2 Blood analysis 
 
The CD4/CD8+T cell counts (cells/cells/mm3), viral load (cps/mℓ) and the full blood 
count (consisting of red blood cells (RBC)(x1012/ℓ); haemoglobin (HB)(g/dℓ); 
haematocrit (HCT)(ℓ/ℓ); mean corpuscular haemoglobin (MCH)(pg); mean 
corpuscular haemoglobin concentration (MCHC)(g/dℓ); mean corpuscular volume 
(MCV)(fℓ); platelets (PLT)(x109/ℓ) and white blood cells (WBC)(x109/ℓ) were 
measured in the EDTA blood of each patient. 
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3.10.2.2.a CD4/CD8+T-cell counts 
 
Instrument:  FACSCalibur 
Manufactured by:  Beckton Dickenson 
Principle and methodology:  MultiTEST 4-colour reagents use a time-saving 
lyse/no-wash method for direct immunofluorescence staining of human peripheral 
blood specimens.  When whole blood is added to TruCOUNT tubes containing 
MultiTEST reagents, the fluorochrome-labelled antibodies bind specifically to 
antigens on the surface of lymphocytes.  The FACSCalibur flow cytometer detects 
four fluorescent colours as well as forward scatter and side scatter (BECKTON 
DICKINSON, 2010).   
 
Twenty microliter of MultiTEST CD3/CD8/CD45/CD4 reagent was pipetted at the 
bottom of a TruCOUNT tube.  Then 50µℓ of well mixed blood from each patient was 
added to the bottom of the TruCOUNT tube.  The tube containing the blood and 
reagent was vortexed gently, but thoroughly, to allow proper mixing of the reagent 
and EDTA blood.  It was then incubated for 15 minutes in the dark, at room 
temperature. After incubation 450µℓ FACS Lysing Solution was added and again 
vortexed gently and left in the dark for another 15 minutes. 
 
After preparation, the samples were analyzed on the BD FACSCalibur analyzer 
which uses flowcytometry to determine the CD4-, CD3-, and CD8 positive cells 
(BECKTON DICKINSON, 2010). 
 
Quality assurance: Commercial controls were prepared in accordance with SOP 
and run with each batch of patients’ samples on either a low, medium or high 
Trucount bead control and another control was analyzed with each batch. 
 
3.10.2.2.b Viral load 
 
Instrument: COBAS AmpliPrep and the COBAS TaqMan 
Manufactured by:  COBAS 
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Principle and methodology:  The COBAS AmpliPrep/COBAS TaqMan HIV-1 Test 
was used for the determination of the viral load.  This is a nucleic acid amplification 
test for the quantification of Human Immunodeficiency Virus Type 1 (HIV-1) RNA in 
human plasma, using the COBAS AmpliPrep instrument for automated specimen 
processing and the COBAS TaqMan analyzer for automated amplification and 
detection.  
 
The COBAS AmpliPrep/COBAS TaqMan HIV-1 Test is based on three major 
processes: (1) specimen preparation to isolate HIV-1 RNA; (2) reverse transcription 
of the target RNA to generate complementary DNA (cDNA); and (3) simultaneous 
PCR amplification of target cDNA and detection of cleaved dual-labelled 
oligonucleotide detection probes specific for the test. 
 
The COBAS AmpliPrep/COBAS TaqMan HIV-1 Test permits automated specimen 
preparation followed by automated reverse transcription, PCR amplification and 
detection of HIV-1 target RNA and HIV-1 Quantitation Standard (QS) Armoured 
RNA. The Master Mix reagent contains a primer pair specific for both HIV-1 RNA and 
HIV-1 QS RNA.  The Master Mix was developed to ensure comparable quantitation 
of group M subtypes of HIV-1. The detection of amplified DNA was performed using 
a target-specific and a QS-specific dual-labelled oligonucleotide probe that allowed 
independent identification of HIV-1 amplicon and HIV-1 QS amplicon. The 
quantitation of HIV-1 viral RNA was performed using the HIV-1 QS.  
 
The HIV-1 QS is a non-infectious Armored RNA construct that contains HIV 
sequences with identical primer binding sites as the HIV-1 RNA target, and a unique 
probe binding region that allows HIV-1 QS amplicon to be distinguished from HIV-1 
amplicon.  The HIV-1 QS is added to each specimen at a known copy number and is 
carried through the specimen preparation, reverse transcription, PCR amplification 
and detection of cleaved dual-labelled oligonucleotide detection probes. The COBAS 
TaqMan analyzer calculates the HIV-1 RNA concentrations by comparing the HIV-1 
signal to the HIV-1 QS signal for each specimen and control.  The HIV-1 QS 
compensates for effects of inhibition and controls for the preparation and 
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amplification processes, allowing a more accurate quantitation of HIV-1 RNA in each 
specimen.  
 
Selection of the target RNA sequence for HIV-1 depends on identification of regions 
within the HIV-1 genome that show maximum sequence conservation among the 
various HIV-1 group M subtypes, and HIV-1 group O specimens.  In order to address 
the high genetic variability of the virus, two regions of HIV genome are 
simultaneously targeted for amplification and detection by the COBAS 
AmpliPrep/COBAS TaqMan HIV-1 Test.  Two target-specific and one QS-specific 
dual-labelled oligonucleotide probes permit independent identification of the HIV-1 
amplicon and of the HIV-1 QS amplicon.  Accordingly, the appropriate selection of 
the primers and the dual-labelled oligonucleotide probe is critical to the ability of the 
test to amplify and detect the HIV-1 group M subtypes and HIV-1 group O.  The 
COBAS AmpliPrep/COBAS TaqMan HIV-1 test uses reverse transcription and PCR 
amplification primers that define sequences within the highly conserved regions of 
the HIV-1 gag gene and of the HIV-1 LTR region. 
 
The viral load testing was performed by qualified Medical Technologist/Technicians, 
as per PathCare Laboratories’ SOP for viral load testing. The test can quantify HIV-1 
RNA over a range of 40 – 10 000 000 copies/mℓ (ROCHE, 2007). 
 
Quality assurance: HIV-1 L(+)C, HIV-1 H(+)C and CTM (-) C 
 
3.10.2.2.c Full blood count 
 
Instrument:  Sysmex XT2000i 
Manufactured by: Sysmex® 
Principle and methodology:  The Sysmex XT2000i is an automated haematology 
analyzer for in-vitro diagnostic use in clinical laboratories.  RBC and PLT are 
analyzed by the RBC detector using Hydro Dynamic Focusing.  Haemoglobin is 
analyzed by the HB detector based on the sulfolyser (SLS) haemoglobin detection 
method.  The HCT is a direct measurement on the red cell transducer.  The MCV, 
MCH and MCHC are parameters calculated from the red cell parameters.  The WBC 
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is analyzed with an optical block based on the flow cytometry method, using a 
semiconductor laser (SYSMEX, 2005).   
 
Quality assurance: Three levels of commercial controls were used, namely e-
Checks level 1, 2 and 3.   
 
3.11. STATISTICAL ANALYSIS 
 
Data from this study was analyzed by the STATISTICA® ’98 Edition, Statsoft Inc. 
Software.  Data was presented in both tabled and graphic format using descriptive 
statistics.  Spearman correlation analysis was used to draw comparisons between 
the stage of disease (using the CD4 lymphocyte cell count as an indicator) and the 
nutrient composition of the breast milk.  The chi-square non-parametric analysis was 
used to compare categorical data.  A p-value of less than 0.5 was considered to be 
significant. 
 
3.12. ETHICAL CONSIDERATIONS 
 
3.12.1 Ethical approval 
 
Ethical approval was obtained from the Ethics Committee of the University of the 
Free State (ETOVS nr 108/08) (See Appendix D).  Subjects were informed of the 
relevance of the study and they were requested to participate voluntarily.  Their right 
to withdraw from the study without having to explain their reasons for doing so was 
explained to each participant before she was requested to sign an informed consent 
contract. 
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3.13. SAFETY VARIABLES 
 
3.13.1 Project safety 
 
Blood was collected by registered medical personnel and the breast milk samples by 
the patients themselves.  The samples were not handled by anybody else.  This was 
a routine medical procedure and did not involve any risk to the patient.  
 
3.13.2 Patient safety 
 
Blood and breast milk samples were collected by registered medical personnel and 
sent to PathCare and Mowbray Milk Depot laboratories. 
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  CHAPTER 4  
RESULTS 
 
The socio-economic, breastfeeding, blood and milk analysis data are reflected in this 
chapter by means of figures and tables.  A Spearman correlation coefficient was 
used to determine whether there was a correlation between the immunological data 
(HIV disease progression) and data of milk composition. 
 
4.1   TREATMENT REGIME OF THE STUDY POPULATION 
 
Sixty HIV-infected participants who met the inclusion criteria were selected and 
divided into two groups.  Group one consisted of 30 participants who did not receive 
any treatment for HIV (HIV-infected without treatment group).  The second group 
consisted of 30 participants who did receive treatment for HIV (HIV-infected with 
treatment group).  Figure 4.1 reflects the treatment regime of the selected study 
population.  Fifty percent of the participants did not receive any ARV treatment, 10% 
received dual treatment and 17% was on HAART.  The ARV regime could not be 
established for 23% of the participants. 
 
 
Figure 4.1  The treatment regime for the selected study population (n=60) 
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4.2 SOCIO-ECONOMIC RESULTS 
 
The information gathered was based on the participants’ socio-economic status, the 
highest education that the babies’ caregivers had received (Table 4.1), the number 
of people contributing to the household income (Table 4.2), the employment status of 
the participants (Table 4.3) and whether the participants had access to a 
refridgerator, water and electricity (Figure 4.2).  Based on the above information, the 
following was established: 
 
The table below summarizes the highest education of the baby’s caregiver by group. 
 
Table 4.1  Highest education level of the baby’s caregiver (n=60) 
 
 
 
 
 
 
 
 
 
 
 
 
When comparing the highest education level of the caregivers of the babies, there 
was no significant statistical difference detected between the HIV-infected without 
treatment mothers’ caregivers and the HIV-infected with treatment mothers’ 
caregivers (p=1.000), where a p-value of <0.05 is considered to be significant.  The 
majority of the groups had a secondary education, 80% and 83% respectively, but 
none of the caregivers had any tertiary education, with only a small percentage that 
had no educational training at all (6.67% and 3.33% respectively). 
 
Highest education 
level 
HIV-infected without 
treatment group 
(n=30) 
HIV-infected with 
treatment group 
(n=30) 
None 2 (6.67%) 1 (3.33%) 
Primary 4 (13.33%) 
 
4 (13.33%) 
Secondary 24 (80%) 25 (83.33%) 
Tertiary 0 (0%) 0 (0%) 
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The number of people who contributed to the household income at the time of the 
interview is shown in Table 4.2. 
 
Table 4.2  Number of people contributing to the household income (n=60) 
Number of people 
contributing to household 
 
HIV-infected 
without treatment 
group(n=30) 
 
HIV-infected with 
treatment group 
(n=30) 
  
0 7 (23.33%) 6 (20%) 
 
 
1 17 (56.67%) 22 (73.33%) 
 
 
2 6 (20%) 2 (6.67%) 
 
 
 
No significant difference between the two groups was found when comparing the 
number of people contributing to the household income (p=0.4363).  Twenty three 
percent and 20% of the study group did not have anyone contributing to the 
household at that stage, where the majority of the study population (76.67% and 
80% respectively) had somebody that contributed to the household income. 
 
Table 4.3 indicates the employment status of the participants at the time of the 
interview. 
 
Table 4.3  The employment status of the two groups (n=60) 
Employment 
status 
 
HIV-infected without 
treatment group (n=30) 
 
HIV-infected with treatment 
group (n=30) 
  
Housewife by 
choice 9 (30%) 8 (26.67%) 
 
 
Self employed 1 (3.33%) 0 (0%) 
 
 
Unemployed 16 (53.33%) 21 (70%) 
 
 
Wage/Salary 
earner 4 (13.33%) 1 (3.33%) 
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The majority of both groups were unemployed at the time of the interview, 30% and 
27% of the mothers were a housewife by choice and 13% and 3% earned a 
salary/wages.  No significant statistical difference was detected between the two 
groups (p=0.2645). 
 
The availibility of certain household appliances and needs is reflected in Figure 4.2. 
 
p-value* - indicates a significant difference with a value <0.05 
 
Figure 4.2   The availibility of refridgeration, water source and  electricity 
 supply to the study population 
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More than three quarters of both study groups had access to their own refridgerators 
(80% & 76.67%), tap water in the house (83.33% & 86.67%) and electricity (93.33% 
& 80%) (Figure 4.2).  No significant difference (p=0.8091 for refridgeration, p=0.7484 
for water and p=0.2542 for electricity) was detected between the two study groups 
pertaining to any of the resources indicated in Figure 4.2. 
 
4.3  BREASTFEEDING RESULTS 
 
In both the HIV-infected without treatment group as well as the HIV-infected with 
treatment group there were 29 mothers who breastfed exclusively and only 1 in each 
group who did not breastfeed exclusively. The fact that this woman did not 
exclusively breastfeed will not have any effect on the nutrient composition of the 
breast milk.  The table below shows the number of times the mothers breastfed their 
baby during a 24 hour period.  The whole group indicated that the best nutrition for 
their babies was breast milk. 
 
Table 4.4  Frequency of breastfeeding intervals per 24 hour period (n=58) 
Group 
 N Median 
Lower 
Quartile 
Upper 
Quartile Mean SD Minimum Maximum 
HIV-infected 
without 
treatment 
group 29 7 7 7 6.8 0.9 3 7 
HIV-infected 
with 
treatment 
group 29 7 7 7 6.8 0.8 3 7 
SD=standard deviation 
 
The median (7), minimum (3) and maximum (7) in both of the study groups were the 
same and no significant difference between the two groups was detected for the 
number of times the mothers breastfed their babies (p=0.6779). 
Although vitamin supplementation is recommended for pregnant woman only 12% of 
the participants were drinking a vitamin supplementation (Figure 4.3). 
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Figure 4.3  Vitamin intake of the study population during the study (n=60) 
 
4.4  HAEMATOLOGICAL AND IMMUNOLOGICAL ANALYSIS 
 
Table 4.5 on the next page represents the haematological and immunological 
parameters of the study population. 
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Table 4.5 Haematological and immunological parameters of the study  
 population (n=60) 
Variable 
Group 
n=30 
Normal 
range Median Mean 
Standard 
Minimum Maximum 
p-
value* Deviation 
White blood NT 
4.0 - 11.0 
6.59 6.78 2.31 3.48 13.50 
0.0364* cells (103/μℓ) T 8.38 8.66 3.25 4.35 14.68 
Red blood NT 
3.7 - 5.3 
4.00 3.88 0.54 2.83 4.97 
0.0467* cells (106/μℓ) T 3.47 3.55 0.75 2.10 5.24 
Hemoglobin NT 
12.0-16.0 
11.60 11.42 1.82 6.80 14.70 
0.1352 (g/dℓ) T 10.35 10.71 2.00 7.70 15.30 
Hematocrit NT 
0.35-0.45 
0.36 0.35 0.05 0.21 0.44 
0.1302 (ℓ/ℓ) T 0.33 0.33 0.06 0.21 0.45 
Mean Corposcular NT 
81 - 100 
90.00 91.43 10.88 67.00 123.00 
0.2932 Volume (fℓ) T 92.50 94.60 10.51 74.00 116.00 
Mean Corposcular NT 
28 - 35 
29.00 29.63 3.93 21.00 38.00 
0.3336 Hemoglobin (pg) T 30.00 30.67 4.42 22.00 39.00 
Mean Corposcular NT 
32 - 37 
32.00 32.47 1.66 29.00 37.00 
0.5261 
Hemoglobin Concen- 
tration(g/dℓ) T 32.00 32.03 2.25 25.00 36.00 
Platelets NT 
140 - 420 
346.00 350.83 111.32 150.00 656.00 
0.3516 (103/μℓ) T 310.50 320.70 90.84 124.00 512.00 
Neutrophils NT 
2.0 - 7.5 
3.29 3.89 1.96 1.34 9.46 
0.0594 (103/μℓ) T 4.44 5.36 2.90 1.44 10.82 
Lymphocytes NT 
1.0 - 4.0 
2.04 2.14 0.80 0.92 4.27 
0.2675 (103/μℓ) T 2.37 2.36 0.76 1.10 3.88 
Monocytes NT 
0.0 - 0.8 
0.49 0.51 0.18 0.24 0.98 
0.0117* (103/μℓ) T 0.63 0.71 0.36 0.23 1.94 
Eosinophils NT 
0.0 - 0.4 
0.16 0.21 0.23 0.02 1.07 
0.9116 (103/μℓ) T 0.13 0.20 0.20 0.01 0.91 
Basophils NT 
0.0 - 0.1 
0.30 0.03 0.01 0.01 0.07 
0.8725 (103/μℓ) T 0.02 0.03 0.03 0.01 0.06 
CD3 cell count NT 
1100-1700 
1756.00 1770.93 735.25 712.00 3742.00 
0.2739 (cells/mm3) T 1855.50 1919.23 641.95 700.00 3100.00 
CD4+ T cell count NT 
700 - 1100 
430.50 577.97 377.72 138.00 1447.00 
0.5692 (cells/mm3) T 540.00 565.40 287.61 94.00 1528.00 
CD8 cell count NT 
500-900 
1081.50 1138.57 467.13 498.00 2452.00 
0.1882 (cells/mm3) T 1209.50 1285.67 480.51 349.00 2521.00 
CD4:CD8 ratio NT 
1.0 - 1.5 
0.42 0.53 0.31 0.10 1.27 
0.7170 ratio T 0.44 0.47 0.24 0.08 1.18 
HIV-1 viral load NT 
<40 
676.50 37812.07 95462.32 40.00 478135.00 
0.6883 (cps/mℓ) T 788.00 63565.60 191016.80 40.00 777115.00 
p-value *-shows a significant difference with a value <0.05 
NT – HIV-infected without treatment group 
T – HIV-infected with treatment group 
Red values indicates values that fell outside the normal reference values 
79 
 
The median for the haemoglobin, CD4+ T cell count and the CD4:CD8 ratio for the 
HIV-infected group receiving treatment was lower than the reference range.  For the 
HIV-infected with treatment group the red blood cells, haemoglobin, haematocrit, 
CD4+ T cell count and the CD4:CD8 ratio was lower than the reference range (Table 
4.5). 
 
The median value for the basophils, CD3+ T cell count, CD8+ T cell count and viral 
load was higher than the reference range in both of the study groups. 
 
The median CD4+ T cell count was 430.5 with the lowest count being 138 and the 
highest 1447 for the HIV-infected without treatment group.  For the HIV-infected with 
treatment group the median was 540 with the lowest CD4+ T cell count being 94 and 
the highest value 1528 (Table 4.5). 
 
The median viral load for the HIV-infected without treatment group was 676.50 and 
for the HIV-infected with treatment group the median was 788. 
 
The only variables that showed a significant statistical difference between the HIV-
infected without treatment group and the HIV-infected with treatment group was 
WBC (p=0.0364), RBC (p=0.0467) and monocytes (p=0.0117). 
 
4.5  MILK COMPOSITION ANALYSIS 
 
The data of the milk composition analysis of the study population is summarized in 
Table 4.6. 
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Table 4.6  Milk composition data of the study population (n=60) 
Variable 
Group 
n=30 Median Mean 
Standard 
Minimum Maximum 
p-
value* 
 
Normal Deviation 
Fat NT 3.10 4.32 4.54 1.30 26.90 
0.9117 
 
4.5b (%) T 3.25 4.24 3.79 0.40 21.20 
Proteiens NT 1.80 2.04 1.50 0.50 7.50 
0.3359 
 
1.1b (%) T 2.00 2.76 2.65 0.30 11.10 
Lactose NT 5.45 5.46 1.52 1.90 7.80 
0.1759 
 
6.8b (%) T 4.90 5.14 1.45 1.80 7.60 
Total NT 10.95 11.96 3.68 6.10 29.10 
0.5296 
 
12.6b Solids (%) T 11.10 11.10 3.65 2.30 20.20 
Energy NT 61.50 70.20 39.19 33.00 263.00 
0.4285 
60–
75a (kcal/100mℓ) T 57.50 63.57 23.84 20.00 132.00 
Calcium NT 4.43 4.49 1.57 0.65 8.15 
0.6572 
2.5–
3.0a (mmol/ℓ) T 4.53 4.60 1.40 0.50 7.05 
Phosphate NT 1.18 1.34 0.72 0.50 2.95 
0.8997 
1.3–
1.6a 
(mmol/ℓ) T 1.20 1.42 0.97 0.50 4.00 
p-value *- shows a significant difference with a value <0.05 
NT – HIV-infected without treatment group 
T – HIV-infected with treatment group 
a –  Values obtained from Jenness, 1979. 
b -  Values obtained from Mcgill University, 2012 
 
The fat percentage of the HIV-infected group without treatment had a median value 
of 3.10 with a minimum of 1.30 and a maximum of 26.90.  The HIV-infected with 
treatment group had a median of 3.25 with a minimum value of 0.40 and a maximum 
value of 21.20. 
 
The percentage protein for the HIV-infected without treatment group was 1.80 with a 
minimum protein value of 0.50 and a maximum value of 7.50, for the HIV-infected 
with treatment group the median value was 2.00 with a minimum value of 0.30 and a 
maximum value of 11.10. 
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The median of the percentage lactose for the HIV-infected without treatment group 
was 5.45 with a minimum value of 1.90 and a maximum value of 7.80.  For the HIV-
infected with treatment group the median was 4.90 with a minimum of 1.80 and 
maximum of 7.60 (Table 4.6). 
 
The percentage total solids median for the HIV-infected without treatment group was 
10.95 with the minimum being 6.10 and the maximum 29.10 and for the HIV-infected 
with treatment group the median was 11.10 with a minimum value of 2.30 and a 
maximum value of 20.20. 
 
The energy content of the HIV-infected without treatment group had a median value 
of 61.50 with a minimum of 33 and a maximum of 263.  For the HIV-infected with 
treatment group the median was 57.50 and here the minimum was 20 and the 
maximum was 132 (Table 4.6). 
 
The median for the calcium content of the milk for the HIV-infected without treatment 
group was 4.43 with a minimum value of 0.65 and a maximum of 8.15, were as the 
content for the HIV-infected with treatment group was 4.53 with a minimum of 0.50 
and a maximum of 7.05. 
 
The median phosphate content was 1.18 for the HIV-infected without treatment 
group, with a minimum of 0.50 and a maximum of 2.95.  For the HIV-infected with 
treatment group the median was 1.20 with a minimum value of 0.50 and a maximum 
value of 4.00 (Table 4.6). There was no significant difference detected in the 
composition of the milk between the two groups (see Table 4.6).
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4.6  CORRELATION BETWEEN THE IMMUNOLOGICAL PARAMETERS AND 
BREAST MILK DATA 
 
Table 4.7 reflects the Spearman Correlation Coefficient (r) and the p-values between 
the immunological parameters and the breast milk of the HIV-infected group without 
treatment. 
 
 If p <0.05: then there is a significant correlation between the two variables. 
 If p ≥ 0.05: then there is no significant correlation between the two variables. 
 A (-) r-value implies a weak negative relationship. 
 A (+) r-value near 1 implies a strong relationship. 
 
Table 4.7  Spearman correlation coefficient and p-values between the 
 immunological parameters and breast milk of the HIV-infected 
 without treatment (n=30) 
  
Fat 
(%) 
Proteiens 
(%) 
Lactose 
(%) 
Total 
Solids 
(%) 
Energy 
(kcal/100mℓ) 
Calcium 
(mmol/ℓ) 
Phos-
phate 
(mmol/ℓ) 
CD4+ T cell 
count  
r-value 0.17979 -0.09472 0.09122 0.15961 0.13426 0.27051 0.35349 
p-value  0.3418 0.6186 0.6316 0.3995 0.4794 0.1482 0.0553 
CD4:CD8 
ratio 
r-value 
 
-0.0135 0.15942 0.05153 0.06674 0.00101 0.17401 0.19558 
p-value 0.9436 0.4001 0.7868 0.726 0.9958 0.3578 0.3003 
HIV-1 viral 
load 
r-value 0.21235 0.04592 -0.06731 0.36787 0.29869 -0.0818 -0.1263 
p-value 0.2599 0.8096 0.7238 0.0455* 0.1089 0.6674 0.506 
p-value *-shows a significant difference with a value <0.05 
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The only statistically significant difference between the immunological parameters 
and breast milk was found between the HIV-1 viral load and percentage total solids 
in breast milk for the HIV-infected without treatment group (p=0.0455). 
 
Negative correlations were found between the CD4+ T cell count and percentage 
protein, CD4:CD8 ratio and the percentage fat of the milk, HIV-1 viral load and 
percentage lactose, calcium (mmol/ℓ) as well as phosphate (mmol/ℓ).  This implies 
that when the one parameter goes up the other parameter will decline and vice 
versa.  However, these were all weak negative relationships.  A value near 1 is 
regarded as having a strong correlation, 0.5 is regarded as having a moderate 
correlation and nearer to 0 as having a weak correlation.  If the value is negative a 
value near -1 will have a strong negative correlation and nearer to 0 will have a weak 
negative correlation.  None of the positive correlations were strong correlations 
(Table 4.7).  
 
Table 4.8 reflects the Spearman Correlation Coefficient (r) and the p-values between 
the immunological parameters and the breast milk of the HIV-infected without 
treatment group. 
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Table 4.8   Spearman correlation coefficient and p-values between the
 immunological parameters and breast milk of the HIV-infected 
 with treatment (n=30) 
p-value *-shows a significant difference with a value <0.05 
 
The only statistically significant p-value between the immunological parameters and 
breast milk of the HIV-infected with treatment group was found between the CD4+ T 
cell count and percentage total solids (p=0.032) as well as the energy (kcal/100mℓ) 
content of the milk (p=0.0315). 
 
For the HIV-infected with treatment group negative correlations where found for the 
CD4+ T cell count with percentage fat, percentage protein, percentage lactose, 
percentage total solids and energy (kcal/100mℓ) as well as for the CD4:CD8 ratio 
with percentage lactose and the HIV-1 viral load with percentage protein and 
phosphate (mmol/ℓ).  Again, these were all weak positive correlations.  None of the 
positive correlations had a strong relationship (Table 4.8). 
 
 
  
Fat 
(%) 
Proteiens 
(%) 
Lactose 
(%) 
Total 
Solids 
(%) 
Energy 
(kcal/100mℓ) 
Calcium 
(mmol/ℓ) 
Phos-
phate 
(mmol/ℓ) 
CD4+ T cell 
count 
r-value -0.22426 -0.17972 -0.119 -0.39223 -0.39349 0.20946 0.21529 
p-value 0.2335 0.342 0.5311 0.032* 0.0315* 0.2666 0.2532 
CD4:CD8 
ratio 
r-value 0.22592 0.08438 -0.09285 0.05132 0.07657 0.0697 0.13032 
p-value 0.23 0.6575 0.6255 0.7877 0.6876 0.7144 0.4924 
HIV-1 viral 
load 
r-value 0.03942 -0.11435 0.1083 0.09673 0.09304 0.06204 -0.02653 
p-value 0.8362 0.5474 0.5689 0.6111 0.6248 0.7447 0.8893 
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  CHAPTER 5 
DISCUSSION 
 
An HIV-infected mother can transmit the virus to her child during pregnancy, labour, 
delivery and through breast milk.  When infants are not breastfed it is very difficult to 
balance the threat of infants acquiring HIV through breastfeeding versus the higher 
risk of death from other causes other than HIV like malnutrition and illnesses such as 
diarrhoea and pneumonia (WHO, 2010d).  One of the most significant ways to 
reduce infant mortality rates is early and exclusive breastfeeding.   
 
The possibility of transmission of HIV through breastfeeding can be reduced greatly 
by giving antiretroviral drugs to the HIV-infected mother or the HIV-exposed infant.  A 
benefit that is closely associated with breastfeeding is that these mothers can offer 
their infants the same protection against the most common causes of child deaths 
(WHO, 2010d). 
 
This chapter will discuss the socio-economic factors, breastfeeding data, blood and 
milk analysis data as well as correlation between the immunological and breast milk 
data. 
 
5.1  SOCIO-ECONOMIC FACTORS 
 
If the sole consideration was to prevent HIV-infection through breast milk, infected 
mothers would be advised not to breastfeed but to give their baby formula milk.  
However, HIV-infection is not the only consideration.  It is important for infected 
mothers living in poor households in developing countries to consider risks related 
with not breastfeeding carefully.  In terms of serious morbidity and mortality the risks 
are much higher in poor households with inadequate sanitation, unsafe and scarce 
water supplies, no refrigeration, poor health services, and little knowledge of hygiene 
(Latham and Preple, 2000). 
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Socio-economically disadvantaged people have more restricted educational 
opportunities, and are at an increased risk for HIV infection (Klatt, 2011).  Young 
women from lower quintiles and rural areas are less likely to have truthful knowledge 
of HIV and AIDS (UNICEF, 2010).  They may often not have access to HIV testing 
and often lack access to antiretroviral therapy following infection (Klatt, 2011).  The 
majority of this sample group had a secondary education with no difference between 
the two groups (Table 4.1).  Most of the women had one individual who contributed 
to the household income with nearly a fifth of the participating women having no one 
that contributed to the household income (Table 4.2).  More than 50% of the women 
were unemployed, this being higher than South Africa’s unemployment rate of 25.5% 
for the years 2000 to 2012 (Trading economics, 2012). Only a small percentage was 
housewives by choice (Table 4.3).  Child mortality is higher among children living in 
rural areas, in less educated communities and in the poorest households (WHO, 
2012).  The risk of a child dying before five years of age in a low-income country is 
about 18 times higher than that of one from a high-income country (WHO, 2012).  
 
With no difference between the two groups, the majority of the participating women 
had electricity, tap water and a refrigerator in their homes (Figure 4.2).  The 
presence and availability of these resources makes it more feasible for the women to 
formula feed if contamination, education and household income are not taken into 
account.  Clinics often cannot supply formula, and with more than 50% of these 
women being unemployed and only having one individual that contributed to the 
household income, mothers often need to mix feed if the option to formula feed is 
chosen,  increasing the infants risk to become HIV-infected. 
 
5.2  BREASTFEEDING  
 
Infant formula is not equivalent in nutrition to breast milk. It does not contain all the 
essential nutrients or antibodies to protect children from diarrhoea, pneumonia or 
malnutrition (Bloemen, 2012).   
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Malnutrition contributes to more than one-third of all under-five deaths (WHO, 2012).  
Globally, 30% of children under five are estimated to be stunted and 18% have low 
weight-for-height, mostly as a consequence of poor feeding and repeated infections 
(WHO, 2010d).  According to the Convention on the Rights of the Child (WHO, 
2010d), every infant and child has the right to good quality nutrition.  The challenge 
is to balance out the risk of deaths from causes other than HIV, in particular 
malnutrition and serious illnesses such as diarrhoea and pneumonia when choosing 
not to breastfeed (WHO, 2010d). 
 
South Africa is one of the 12 countries in the world where infant mortality has been 
on the increase. That is why the South African policy on breastfeeding has changed 
to adopt the WHO recommendations for a single infant feeding strategy, namely 
exclusive breastfeeding also for HIV-infected mothers as enshrined in the Tshwane 
Declaration, August 2011 (Goga et al., 2012).  One of those recommendations is that 
the provision of milk formula through hospitals and clinics will no longer be practiced 
except when recommended by an authorised health practitioner (Motsoaledi, 2011). 
 
In the past, the most important aspect was to prevent MTCT of HIV through 
breastfeeding and the low percentage – 8% – of exclusive breastfeeding in South 
Africa can be ascribed to this (Bloemen, 2012).  There was a high prevalence of 
breastfeeding in both groups of women - this could likely be due to the fact that a 
high percentage of the individuals had a secondary education (Table 4.1). The fact 
that all the mothers indicated that breast milk was the best feeding option for their 
infants is a good indication that they had were well informed at the hospital/clinic 
about breastfeeding and the advantages of breast milk.  Breastfeeding mothers who 
strive to exclusively breastfeed are faced with multiple challenges (Agunbiade and 
Ogunleye, 2012) and health system support of breastfeeding is an important factor 
for success.  It is important that hospitals develop ways to promote breastfeeding 
and support programs as well as closely monitor outcomes from these services on 
an ongoing basis (Kuan et al., 1999). 
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Mothers need to be supported for their children to be optimally breastfed.  Some of 
the actions that help protect, promote and support breastfeeding include: 
 adoption of policies such as the International Labour Organization Maternity 
Protection Convention 183 and the International Code of Marketing of Breast-milk 
Substitutes; 
 implementation of the Ten Steps to successful breastfeeding specified in the 
Baby-friendly Hospital Initiative, including: 
o Skin-to-skin contact between mother and baby immediately after birth and 
initiation of breastfeeding within the first hour of life  
o Breastfeeding on demand (that is, as often as the child wants, day and 
night) 
o Babies should not be given additional food or drink, not even water. 
(WHO, 2010d) 
 
Giving ARVs to either the HIV-infected mother or the HIV-exposed infant significantly 
reduces the risk of transmitting HIV through breastfeeding.  This enables HIV-
infected mothers to breastfeed, with low risk (1-2%) of transmission (WHO, 2010d). 
 
5.3  HAEMATOLOGICAL AND IMMUNOLOGICAL PARAMETERS  
 
HIV-infected populations are burdened with malnutrition and numerous studies have 
reported that these deficiencies impair immune response and are associated with 
accelerated HIV disease progression (Dreyfuss and Fawzi, 2002).  It is not clear 
whether HIV disease progression and its metabolic impact on the mother will affect 
the nutrient composition of breast milk in these immune-compromised individuals.  
 
When comparing the haematological variables that were analysed, the white blood 
cells indicated a significant difference (p=0.0364) between the HIV-infected without 
treatment group and the HIV-infected with treatment group (Table 4.5).  The HIV-
infected with treatment group had a higher total white blood cell count (Table 4.5).  
This could be attributed to the fact that the treatment aided in the strengthening of 
the immune system. Although the neutrophil and lymphocyte count did not have a 
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significant p-value (p=0.0594 & p=0.2675 respectively) the treatment group had a 
slightly higher absolute neutrophil and lymphocyte count, giving the body better 
protection against infections. HIV attacks white blood cells and a condition called 
leukopenia can develop which makes the body more prone to infections (PDR Health 
Physicians Desk reference, 2011).  Advanced HIV disease can cause neutropenia 
which could then result in a lower total white blood cell count (AIDS.org, 2007). 
 
The red blood cells also indicated a significant p-value (p=0.0467) between the two 
groups.  The HIV-infected with treatment group had a lower red blood cell count.  
This is likely be ascribed to the fact that drugs used to treat HIV and to combat other 
infections often cause blood disorders. They impair the production of leucocytes, red 
blood cells and/or platelets in the bone marrow (PDR Health Physicians Desk 
reference, 2011).  
 
Both the groups were anemic with hemoglobin levels below normal.  Anemia is 
common in pregnant women, particularly HIV-infected women in resource limited 
settings (WHO, 2010b).  Bone marrow suppression is common in people with 
advanced HIV infection and this causes anemia to be a chronic disease.  This 
impairment is due to the release of inhibitory substances and low levels of the 
hormone erythropoietin (PDR Health Physicians Desk reference, 2011) as well as 
the fact that HIV causes disturbances in iron metabolism (WHO, 2003).  The HIV-
infected with treatment group had a slightly decreased heamatocrit which can also 
be attributed to the anemia (AIDS.org, 2007). 
 
Iron-folate supplementation is a standard component of antenatal care for preventing 
anemia and improving fetal iron stores.  The WHO recommends that daily iron-folate 
supplements must be taken for six months during pregnancy to prevent anemia, and 
twice-daily to treat severe anemia (WHO, 2003).  Only 12% of all the participants 
were taking vitamin supplements and this could account for the fact that the women 
were anemic.   
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The cluster of differentiation 3 positive (CD3+) T cell count had increased above the 
normal reference value in both groups.  The CD3+ T cell count is the number of CD8+ 
T cells plus the number of CD4+ T cells and the natural killer cells.  The CD3+ T cell 
count increases because the CD8+ T cells proliferate exponentially as CD4+ T cells 
are depleted. The CD8+ T cell proliferation is driven mainly by HIV RNA levels 
(Catalfamo et al., 2011).  
 
The CD4+ T cell count was lower than the reference range in both groups although 
there was no significant difference detected in the p-value (p=0.5692).  The 
pathogenesis of HIV infection is largely attributed to the decrease in the number of T 
cells that have the CD4 receptor.  The immune status of a person living with HIV can 
be assessed by measuring the absolute number of CD4+ T cells.  This is also the 
way to assess the severity of HIV-related immunodeficiency.  The progressive 
decline in the number of CD4+ T cells is associated with progression of HIV disease 
(Hargreaves, 2007; WHO, 2007).  The CD4+ T cell count had a higher median value 
in the HIV-infected with treatment group which correlates with the literature that the 
CD4+ T cell count usually increases in response to an effective ART combination 
(WHO, 2007) (see Table 4.5).  A possible explanation for the low CD4+ T cell count 
of 94 in the HIV-infected with treatment group could be that the patients had just 
commenced with ART (unfortunately the duration of the treatment was not recorded 
in the current patient files) or the patient could have had a resistance against the 
treatment due to mutations (WHO, 2013; Sen, 2007).  The lowest CD4+ T cell count 
in both groups fell in the severe immune compromised category.  When categorizing 
the two groups according to the immunological classification, the HIV-infected 
without treatment group fell in the “mild immunodeficiency” group and the HIV with 
treatment group in the “not significant” group (WHO, 2007) (Table 4.5).   
 
During the course of the illness, the virus particles increase and the number of CD4+ 
T cells decline (Department for work and pensions, 2009).  The best laboratory 
measurement for determining the progression of AIDS is the viral load.  Prior to any 
immune response the HIV-1 RNA typically exceeds 10,000 copies/mℓ.  According to 
Klatt (2011), the initial viral load in females, following HIV infection, is 15,103 
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copies/mℓ.  The median HIV-1 viral load for the HIV with treatment group was higher 
than the HIV-infected without treatment group. This pattern could have been 
explained better if the duration of ART had been established, since literature 
suggests that individuals receiving ART should have a lower HIV-1 viral load 
(Hargreaves, 2007) (Table 4.5).  Persons starting therapy with high plasma levels of 
HIV (>100,000 copies/mℓ) may take longer to suppress.  The failure to suppress 
viremia to <50 copies/mℓ by 16 to 24 weeks of therapy suggests poor adherence, 
inadequate drug absorption or drug resistance (Klatt, 2011; Hargreaves, 2007).  The 
viral load can also be useful in predicting clinical progression (Panel on Antiretroviral 
Guidelines for Adults and Adolescents, 2011). 
 
5.4  MILK COMPOSITION 
 
The analyzed milk data of the study population yielded no p-value of great 
significance, suggesting that there was no statistically significant difference recorded 
of the measured nutrients between mothers receiving treatment and those who did 
not receive any treatment for HIV.  When looking at the measured nutrients from this 
study there was a difference between the minimum and maximum values that were 
obtained for the nutrients and this can be seen in the standard deviation values 
(Table 4.6).  Previous studies suggest that race, age, parity, and/or diet fail to have a 
great effect on milk composition (Jenness, 1979) but that milk does evolve to meet 
the changing needs of the baby during growth and maturation (Lönnerdal, 1986).  
The milk expressed during the first minutes of feeding also has a lower fat content 
than that in the later stage of breastfeeding (Wagner, 2010).  Other studies suggest 
that although breast milk composition is remarkably stable around the world, it can 
change slightly with different maternal diets and under different environmental 
conditions and that the fat content can vary with the mother’s diet (Katz, 2006). 
 
Variation in fat content affects the energy content of the breast milk, calories being 
associated with significant lessening of energy intake for the infant (Jelliffe and 
Jelliffe, 1978).  A minimum fat value of 0.40% with only 20kcal/100mℓ was recorded.  
These values are less than the normal values for breast milk and these infants’ 
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calorie intake will not be sufficient for proper growth and development.  Cholesterol, 
triglycerides, short-chain fatty acids and long chain fatty acids are present in fat.  
Long chain polyunsaturated fatty acids - docosahexanoic acid (DHA) - and 
arachidonic acid (ARA) are important for the neurological development of a child, 
therefore these two fatty acids may be considered essential fatty acids (Wagner, 
2010; WHO, 2009; Hamosh, 2001; Jenness, 1979). 
 
Previous studies show that the lactose content does not seem to vary a lot – even in 
poorly nourished mothers (Lönnerdal, 1986; Jelliffe and Jelliffe, 1978).  This study, 
however, showed a difference in the minimum and maximum values that were 
obtained for lactose (see Table 4.6) with the minimum value less than the normal 
value for lactose.  Carbohydrates aids in providing protection against infections 
(WHO, 2009) and infants need constant protection against exposure to possible 
pathogens that could cause various infections increasing their mortality risk. 
 
Calcium levels in poorly fed mothers range from normal to somewhat low 
concentrations (Lönnerdal, 1986).  Calcium levels for this study ranged from low to 
high with the median value of both groups above normal. (See Table 4.6).  Adequate 
calcium intake is essential for infant health and cases of rickets have been 
associated with low concentrations of breast milk calcium (Kent, Arthur, Mitoulas, 
Hartman, 2009). 
 
The Spearman Correlation Coefficient was used to determine if HIV disease 
progression would have an influence on the nutrients that were measured in this 
research (Table 4.7 & Table 4.8).  For the HIV-infected without treatment group, a 
significant correlation (p=0.0455) was found between the HIV-1 viral load and 
percentage total solids in breast milk.  Total Solids comprises of fat, protein, lactose, 
minerals, vitamins and enzymes (McGill University, 2012).  Since no correlation 
could be shown in the percentage of fat, percentage of protein, percentage of 
lactose, calcium (mmol/ℓ) or phosphate (mmol/ℓ) the difference could be in other milk 
components that were not measured in my study. 
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There was a negative correlation between the CD4+ T cell count and the protein (%) 
content of the breast milk of the HIV-infected without treatment group, but it was a 
weak negative correlation (Table 4.7).  This implies that when the CD4+ T cell count 
increases the protein (%) content of milk will decrease and vice versa.  The 
CD4:CD8 ratio and the fat (%) content also delivered a weak negative correlation as 
well as HIV-1 viral load (copies/mℓ) with percentage lactose, calcium (mmol/ℓ) and 
phosphate (mmol/ℓ) in the breast milk of the HIV-infected without treatment group. 
 
For the HIV-infected with treatment group the only positive correlation was between 
the CD4+ T cell count and the percentage total solids and energy (kcal/100mℓ) 
content of the breast milk (Table 4.8).  A weak negative correlation between these 
parameters could also be shown.  Furthermore, there was also a weak negative 
correlation between the CD4+ T cell count (cells/mm3) and percentage fat, 
percentage protein and percentage lactose.  Lactose and the CD4:CD8 ratio also 
had a weak negative correlation.  The HIV-1 viral load had a weak negative 
correlation between percentage protein and phosphate (mmol/ℓ).   
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  CHAPTER 6 
CONCLUSION 
 
When a mother decides to exclusively breastfeed for the first six months it holds 
benefits for both the mother and for the infant, with one of those benefits being the 
protection against gastro-intestinal infections.  The earlier breastfeeding is initiated 
the lower the risk for newborn mortality due to diarrhoea and other infections (WHO, 
2010d). 
 
In developing countries breastfeeding is very important for child survival but may 
also result in HIV infections in infants.  Thus, the same economic and development 
inequities that make breastfeeding so critical to infant survival make formula feeding 
inaccessible, unfeasible, unaffordable, unsustainable and unsafe (not AFASS) for 
most families (Humhrey, 2010). 
 
When deciding on the method of feeding the infant in HIV-positive mothers the risk of 
transmission of HIV to the infant and the risk of acquiring other potential fatal 
diseases from contaminated foods and malnutrition must be weighed.  There are no 
known studies on the effect of HIV disease progression on the nutrient composition 
of breast milk. 
 
No significant difference in the nutrients that were analysed could be revealed 
between HIV-infected mothers who received treatment and HIV-infected mothers 
who did not receive any treatment. HIV disease progression did not have an 
influence on the nutrients that were analysed and no strong positive correlation could 
be established between the immunological markers of HIV disease progression and 
the analysed nutrients in the breast milk.  Taking this into consideration, HIV mothers 
can breastfeed their babies even if their HIV is at a more advance phase, but the 
emphasis should be placed on exclusive breastfeeding and getting the needed 
support to breastfeed.  
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Breastfeeding women should get support from their family, the community and 
healthcare workers in their decision to breastfeed their infant, but with South Africa’s 
changed policy on breastfeeding the percentage of women who exclusive breastfeed 
should increase.  This study showed that there was no correlation between the 
nutrient composition of breast milk and HIV disease progression, but that compliance 
in using ARV treatment is of utmost importance to reduce the HIV RNA levels in 
breast milk, minimising the transmission of the HIV through breast milk.  Infant 
formula does not contain all the essential nutrients or antibodies to protect children 
from diarrhoea, pneumonia or malnutrition.  Even severe immune compromised 
mothers can breastfeed their infants – and when this is done in conjunction with the 
current ARV recommendations for mothers and infants – breast is best. 
 
Only a limited number of milk constituents could be analyzed due to the difficulty of 
analysing the milk and the high cost of the milk analysis.  To get mothers to 
participate in the study voluntarily was also very difficult – this could have been 
because of the stigmatization that still exists around HIV.  Although the whole 
process was handled with complete confidentiality, mothers were reluctant to 
participate and this yielded a small study group.  This study would have been more 
informative had the study population been larger. 
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  APPENDIXES  
 
APPENDIX A 
 
RECOMMENDED INFANT AND YOUNG CHILD FEEDING PRACTICES  NOT 
TAKING HIV/AIDS INTO CONSIDERATION. 
 
WHO and the United Nations Children’s Fund (UNICEF) global recommendations 
(2009) for optimal infant feeding as set out in the Global Strategy are: 
 Exclusively breastfeeding for 6 months (180 days) 
 Nutritionally adequate and safe complimentary feeding starting from the age 
 of 6 months with continued breastfeeding to up to 2 years of age or beyond 
 (WHO, 2009). 
Exclusive breastfeeding means that an infant receives only breast milk from his or 
her mother or a wet nurse, or expressed breast milk and no other liquids or solids. 
Not even water, with the exception of oral rehydration solution, drops or syrups 
consisting of vitamins, mineral supplements or medicines (WHO, 2009). 
Complementary feeding is defined as the process starting when breast milk is no 
longer sufficient to meet the nutritional requirements of infants, and therefore other 
foods and liquids are needed, along with breast milk.  The target range for 
complimentary feeding is generally taken to be 6 to 23 months of age, even though 
breastfeeding may continue beyond two years (WHO, 2009). 
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APPENDIX B 
ACCEPTABLE MEDICAL REASONS FOR USING BREAST MILK SUBSTITUTES 
(WHO, 2009) 
Infants who should not receive breast milk or any other milk except specialized 
formula 
 Infants with classic galactosemia: a special galactose-free formula is 
needed. 
 Infants with maple syrup urine disease: a special formula free of leucine, 
 isoleucine and valine is needed.  
 Infants with phenylketonuria: a special phenylalanine-free formula is 
needed (some breastfeeding is possible, under careful monitoring). 
 
Infants for whom breast milk remains the best feeding option but who may 
need other food in addition to breast milk for a limited period: 
 Infants born weighing less than 1500 g (very low birth weight). 
 Infants born at less than 32 weeks of gestational age (very pre-term). 
 Newborn infants who are at risk of hypoglycaemia by virtue of impaired 
metabolic adaptation or increased glucose demand (such as those who 
are preterm, small for gestational age or who have experienced 
significant intrapartum hypoxic/ischemic stress, those who are ill and 
those whose mothers are diabetic);  if their blood sugar fails to respond 
to optimal breastfeeding or breast-milk feeding. 
 
Maternal conditions that may justify permanent avoidance of 
 breastfeeding: 
 HIV infection: if replacement feeding is acceptable, feasible, affordable, 
 sustainable and safe. 
 
113 
 
Maternal conditions that may justify temporary avoidance of breastfeeding: 
 Severe illness that prevents a mother from caring for her infant, for 
example: sepsis. 
 Herpes simplex virus type 1 (HSV-1): direct contact between lesions on 
the mother’s breasts and the infant’s mouth should be avoided until all 
active lesions have resolved. 
 Maternal medication: 
o sedating psychotherapeutic drugs, anti-epileptic drugs and opiates and 
their combinations may cause side effects such as drowsiness and 
respiratory depression and are better avoided if a safer alternative is 
available ; 
o radioactive iodine-131 is better avoided given that safer alternatives are 
 available - a mother can resume breastfeeding about two months after 
receiving this substance; 
o excessive use of topical iodine or iodophors (e.g., povidone-iodine), 
especially on open wounds or mucous membranes, can result in thyroid 
suppression or electrolyte abnormalities in the breastfed infant and 
should be avoided; 
o cytotoxic chemotherapy requires that a mother stops breastfeeding 
during therapy. 
 
Maternal conditions during which breastfeeding can still continue, 
although health problems may be of concern: 
 Breast abscess: breastfeeding should continue on the unaffected 
breast; feeding from the affected breast can resume once treatment has 
started 
 Hepatitis B: infants should be given hepatitis B vaccine, within the first 
48 hours or as soon as possible thereafter 
 Hepatitis C. 
 Mastitis: if breastfeeding is very painful, milk must be removed by 
expression to prevent progression of the condition. 
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 Tuberculosis: mother and baby should be managed according to 
national tuberculosis guidelines 
 Substance use: 
o maternal use of nicotine, alcohol, ecstasy, amphetamines, cocaine and 
related stimulants has been demonstrated to have harmful effects on 
breastfed babies; 
o alcohol, opioids, benzodiazepines and cannabis can cause sedation in 
both the mother and the baby.  
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APPENDIX C 
Questionaire 
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APPENDIX D 
Ethical approval 
 
